Perhydrolases for enzymatic peracid generation

ABSTRACT

Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos.61/102,505; 61/102,512; 61/102,514; 61/102,520; 61/102,531; and61/102,539; each filed Oct. 3, 2008, each of which is incorporated byreference herein in their entireties.

FIELD OF THE INVENTION

This invention relates to the field of enzymatic peroxycarboxylic acidsynthesis and in situ enzyme catalysis. More specifically, compositionsand methods related to variant enzyme catalysts having improvedperhydrolysis activity are provided. At least one peroxycarboxylic acidis produced at sufficient concentrations as to be efficacious for thedisinfection or sanitization of surfaces, medical instrumentsterilization, food processing equipment sterilization, and suitable foruse in textile and laundry care applications such as bleaching,destaining, deodorizing, disinfection or sanitization.

BACKGROUND OF THE INVENTION

Peroxycarboxylic acid compositions have been reported to be effectiveantimicrobial agents. Methods to clean, disinfect, and/or sanitize hardsurfaces, meat products, living plant tissues, and medical devicesagainst undesirable microbial growth have been described (e.g., U.S.Pat. No. 6,545,047; U.S. Pat. No. 6,183,807; U.S. Pat. No. 6,518,307;U.S. Pat. No. 5,683,724; and U.S. Patent Application Publication No.2003/0026846). Peroxycarboxylic acids have also been reported to beuseful in preparing bleaching compositions for laundry detergentapplications (U.S. Pat. No. 3,974,082; U.S. Pat. No. 5,296,161; and U.S.Pat. No. 5,364,554).

Peroxycarboxylic acids can be prepared by the chemical reaction of acarboxylic acid and hydrogen peroxide (see Organic Peroxides, DanielSwern, ed., Vol. 1, pp 313-516; Wiley Interscience, New York, 1971). Thereaction is usually catalyzed by a strong inorganic acid, such asconcentrated sulfuric acid. The reaction of hydrogen peroxide with acarboxylic acid is an equilibrium reaction, and the production ofperoxycarboxylic acid is favored by the use of an excess concentrationof peroxide and/or carboxylic acid, or by the removal of water.

Some peroxycarboxylic acid-based disinfectants or bleaching agents arecomprised of an equilibrium mixture of peroxycarboxylic acid, hydrogenperoxide, and the corresponding carboxylic acid. One disadvantage ofthese commercial peroxycarboxylic acid cleaning systems is that theperoxycarboxylic acid is oftentimes unstable in solution over time. Oneway to overcome the stability problem is to generate theperoxycarboxylic acid prior to use by combining multiple reactioncomponents that are individually stable for extended periods of time.Preferably, the individual reaction components are easy to store,relatively safe to handle, and capable of quickly producing anefficacious concentration of peroxycarboxylic acid upon mixing.

The CE-7 family of carbohydrate esterases has recently been reported tohave perhydrolase activity. These “perhydrolase” enzymes have beendemonstrated to be particularly effective for producing peroxycarboxylicacids from a variety of carboxylic acid ester substrates when combinedwith a source of peroxygen (See WO2007/070609 and U.S. PatentApplication Publication Nos. 2008/0176299, 2008/176783, and 2009/0005590to DiCosimo et al.; each herein incorporated by reference in theirentireties). Some members of the CE-7 family of carbohydrate esteraseshave been demonstrated to have perhydrolytic activity sufficient toproduce 4000-5000 ppm peracetic acid from acetyl esters of alcohols,diols, and glycerols in 1 minute and up to 9000 ppm between 5 minutesand 30 minutes once the reaction components were mixed (DiCosimo et al.,U.S. Patent Application Publication No. 2009/0005590).

The ability to commercialize many bleaching and/or disinfection productsbased on enzymatic perhydrolysis may be dependent upon the cost ofproducing the enzyme catalyst. The use of enzyme catalysts havingimproved perhydrolytic activity may reduce the amount of enzyme catalystin the commercial product and may significantly decrease the cost ofproduction. As such, there remains a need to identify enzyme catalystshaving improved perhydrolytic activity.

Further, enzymatic perhydrolysis is typically conducted using aqueousreaction conditions. Enzyme catalysts having perhydrolytic activitytypically exhibit hydrolytic activity, forming carboxylic acids that maylower the pH of the reaction mixture. As such, it is desirable toutilize a perhydrolase that has high selectivity for perhydrolysis of anester to peroxycarboxylic acid relative to hydrolysis of the same esterto carboxylic acid; the “P/H” ratio (rate of perhydrolysis/rate ofhydrolysis) is one method of characterizing the selectivity of aperhydrolase for perhydrolysis.

The problem to be solved is to provide enzyme catalysts characterized byimproved perhydrolytic activity. The improvement may be an increase inperhydrolase specific activity for carboxylic acid esters and/or animprovement in selectivity for perhydrolysis over hydrolysis whenproducing peroxycarboxylic acids from carboxylic acid esters.

SUMMARY OF THE INVENTION

The stated problem has been solved by providing enzyme catalysts havingimproved perhydrolase specific activity and/or improved selectivity forperhydrolysis over hydrolysis when producing peroxycarboxylic acids fromcarboxylic acid esters. More specifically, CE-7 perhydrolase variantsare provided having improved perhydrolase specific activity and/or animprovement in selectivity (i.e., an improvement in the ratio ofperhydrolysis/hydrolysis activity). Compositions and processescomprising the present variants are also provided.

One aspect is for an isolated polynucleotide encoding a polypeptidehaving perhydrolysis activity, said polypeptide being structurallyclassified as a carbohydrate esterase family 7 enzyme and (a) having atleast 95% amino acid sequence identity to SEQ ID NO: 5, SEQ ID NO: 10,SEQ ID NO: 15, SEQ ID NO: 20, or SEQ ID NO: 25, provided that asubstitution to amino acid residue 277 of SEQ ID NO: 5, SEQ ID NO: 10,SEQ ID NO: 15, SEQ ID NO: 20, or SEQ ID NO: 25 is selected from thegroup consisting of serine, threonine, valine, and alanine or (b) havingat least 95% amino acid sequence identity to SEQ ID NO: 30, providedthat a substitution to amino acid residue 278 of SEQ ID NO: 30 isselected from the group consisting of serine, threonine, valine, andalanine. In some embodiments, the polypeptide comprises SEQ ID NOs: 5,10, 15, 20, 25, or 30. In some embodiments, the nucleotide sequencecomprises SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17,18, 19, 21, 22, 23, 24, 26, 27, 28, or 29.

Another aspect is for an isolated polypeptide having perhydrolysisactivity and being structurally classified as a carbohydrate esterasefamily 7 enzyme, said polypeptide having at least 95% amino acidsequence identity to (a) SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 15, SEQID NO: 20, or SEQ ID NO: 25, provided that a substitution to amino acid277 of SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 20, or SEQID NO: 25 is selected from the group consisting of serine, threonine,valine, and alanine; or (b) SEQ ID NO: 30, provided that a substitutionto amino acid 278 of SEQ ID NO: 30 is selected from the group consistingof serine, threonine, valine, and alanine. In some embodiments, thepolypeptide comprises SEQ ID NOs: 5, 10, 15, 20, 25, or 30.

In a further aspect, a process for producing a peroxycarboxylic acidfrom a carboxylic acid ester is provided comprising

-   -   (a) providing a set of reaction components, said components        comprising:        -   (1) a carboxylic acid ester selected from the group            consisting of:            -   (i) one or more esters having the structure

[X]_(m)R₅

-   -   -   -   wherein            -   X is an ester group of the formula R₆C(O)O;            -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl                moiety, optionally substituted with a hydroxyl group or                C1 to C4 alkoxy group, wherein R₆ optionally comprises                one or more ether linkages where R₆ is C2 to C7;            -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl                moiety optionally substituted with a hydroxyl group,                wherein each carbon atom in R₅ individually comprises no                more than one hydroxyl group or no more than one ester                group, and wherein R₅ optionally comprises one or more                ether linkages;            -   m is 1 to the number of carbon atoms in R₅,            -   said one or more esters having solubility in water of at                least 5 ppm at 25° C.;            -   (ii) one or more glycerides having the structure

-   -   -   -   wherein R₁ is a C1 to C7 straight chain or branched                chain alkyl optionally substituted with an hydroxyl or a                C1 to C4 alkoxy group and R₃ and R₄ are individually H                or R₁C(O);            -   (iii) one or more esters of the formula

-   -   -   wherein R₁ is a C1 to C7 straight chain or branched chain            alkyl optionally substituted with an hydroxyl or a C1 to C4            alkoxy group and R₂ is a C1 to C10 straight chain or            branched chain alkyl, alkenyl, alkynyl, aryl, alkylaryl,            alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or            (CH₂CH(CH₃)—O_(n)H and n is 1 to 10;            -   (iv) one or more acetylated monosaccharides, acetylated                disaccharides, or acetylated polysaccharides; and            -   (v) any combination of (i) through (iv);        -   (2) a source of peroxygen; and        -   (3) the polypeptide having perhydrolysis activity as            described above; and

    -   (b) combining said reaction components under suitable aqueous        reaction conditions whereby a peroxycarboxylic acid is produced.

In an additional aspect, a process is provided to disinfect or sanitizea hard surface or inanimate object using an enzymatically-producedperoxycarboxylic acid composition, said process comprising:

-   -   (a) providing a set of reaction components, said components        comprising:        -   (1) a carboxylic acid ester selected from the group            consisting of:            -   (i) one or more esters having the structure

[X]_(m)R₅

-   -   -   -   wherein            -   X is an ester group of the formula R₆C(O)O;            -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl                moiety, optionally substituted with a hydroxyl group or                C1 to C4 alkoxy group, wherein R₆ optionally comprises                one or more ether linkages where R₆ is C2 to C7;            -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl                moiety optionally substituted with a hydroxyl group,                wherein each carbon atom in R₅ individually comprises no                more than one hydroxyl group or no more than one ester                group, and wherein R₅ optionally comprises one or more                ether linkages;            -   m is 1 to the number of carbon atoms in R₅,            -   said one or more esters having solubility in water of at                least 5 ppm at 25° C.;            -   (ii) one or more glycerides having the structure

-   -   -   -   wherein R₁ is a C1 to C7 straight chain or branched                chain alkyl optionally substituted with an hydroxyl or a                C1 to C4 alkoxy group and R₃ and R₄ are individually H                or R₁C(O);            -   (iii) one or more esters of the formula

-   -   -   wherein R₁ is a C1 to C7 straight chain or branched chain            alkyl optionally substituted with an hydroxyl or a C1 to C4            alkoxy group and R₂ is a C1 to C10 straight chain or            branched chain alkyl, alkenyl, alkynyl, aryl, alkylaryl,            alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or            (CH₂CH(CH₃)—O)_(n)H and n is 1 to 10;            -   (iv) one or more acetylated monosaccharides, acetylated                disaccharides, or acetylated polysaccharides; and            -   (v) any combination of (i) through (iv);        -   (2) a source of peroxygen; and        -   (3) the polypeptide having perhydrolysis activity described            above;

    -   (b) combining said reaction components under suitable aqueous        reaction conditions whereby a peroxycarboxylic acid product is        formed;

    -   (c) optionally diluting said peroxycarboxylic acid product; and

    -   (d) contacting said hard surface or inanimate object with the        peroxycarboxylic acid produced in step (b) or step (c) whereby        said surface or said inanimate object is disinfected.

Another aspect is for a peroxycarboxylic acid generating systemcomprising:

-   -   (a) a substrate selected from the group consisting of:        -   (i) one or more esters having the structure

[X]_(m)R₅

-   -   -   wherein        -   X is an ester group of the formula R₆C(O)O;        -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl            moiety, optionally substituted with a hydroxyl group or C1            to C4 alkoxy group, wherein R₆ optionally comprises one or            more ether linkages where R₆ is C2 to C7;        -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl            moiety optionally substituted with a hydroxyl group, wherein            each carbon atom in R₅ individually comprises no more than            one hydroxyl group or no more than one ester group, and            wherein R₅ optionally comprises one or more ether linkages;        -   m is 1 to the number of carbon atoms in R₅, said one or more            esters having solubility in water of at least 5 ppm at 25°            C.;        -   (ii) one or more glycerides having the structure

-   -   -   wherein R₁ is a C1 to C7 straight chain or branched chain            alkyl optionally substituted with an hydroxyl or a C1 to C4            alkoxy group and R₃ and R₄ are individually H or R₁C(O);        -   (iii) one or more esters of the formula

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₂ is a C1 to C10 straight chain or branched chain        alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkylheteroaryl,        heteroaryl, (CH₂CH₂O)_(n), or (CH₂CH(CH₃)—O)_(n)H and n is 1 to        10;        -   (iv) one or more acetylated monosaccharides, acetylated            disaccharides, or acetylated polysaccharides; and        -   (v) any combination of (i) through (iv);    -   (b) a source of peroxygen; and    -   (c) the polypeptide having perhydrolysis activity described        above.

A further aspect is for a process for treating an article of clothing ora textile for bleaching, stain removal, odor reduction, sanitization ordisinfection using an enzymatically-produced peroxycarboxylic acidcomposition, said process comprising:

-   -   (a) providing a set of reaction components, said components        comprising:        -   (1) a carboxylic acid ester selected from the group            consisting of:            -   (i) one or more esters having the structure

[X]_(m)R₅

-   -   -   wherein        -   X is an ester group of the formula R₆C(O)O;        -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl            moiety, optionally substituted with a hydroxyl group or C1            to C4 alkoxy group, wherein R₆ optionally comprises one or            more ether linkages where R₆ is C2 to C7;        -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl            moiety optionally substituted with a hydroxyl group, wherein            each carbon atom in R₅ individually comprises no more than            one hydroxyl group or no more than one ester group, and            wherein R₅ optionally comprises one or more ether linkages;        -   m is 1 to the number of carbon atoms in R₅, said one or more            esters having a solubility in water of at least 5 ppm at 25°            C.;            -   (ii) one or more glycerides having the structure

-   -   -   wherein R₁ is a C1 to C7 straight chain or branched chain            alkyl optionally substituted with an hydroxyl or a C1 to C4            alkoxy group and R₃ and R₄ are individually H or R_(I)C(O);            -   (iii) one or more esters of the formula

-   -   -   wherein R₁ is a C1 to C7 straight chain or branched chain            alkyl optionally substituted with an hydroxyl or a C1 to C4            alkoxy group and R₂ is a C1 to C10 straight chain or            branched chain alkyl, alkenyl, alkynyl, aryl, alkylaryl,            alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or            (CH₂CH(CH₃)—O)_(n)H and n is 1 to 10;            -   (iv) one or more acetylated monosaccharides, acetylated                disaccharides, or acetylated polysaccharides; and            -   (v) any combination of (i) through (iv).        -   (2) a source of peroxygen; and        -   (3) the polypeptide having perhydrolysis activity described            above;

    -   (b) combining said reaction components under suitable aqueous        reaction conditions whereby a peroxycarboxylic acid product is        formed;

    -   (c) optionally diluting said peroxycarboxylic acid product; and

    -   (d) contacting said article of clothing or textile with the        peroxycarboxylic acid produced in step (b) or step (c);        wherein said article of clothing or textile is destained,        deodorized, disinfected, bleached, or a combination thereof.

In a further aspect, a formulation is provided comprising (a) a firstmixture comprising an enzyme catalyst comprising the polypeptide havingperhydrolysis activity described above and a carboxylic acid esterselected from the group consisting of monoacetin, diacetin, triacetinand mixtures thereof; said first mixture optionally comprising a furthercomponent selected from the group consisting of an inorganic or organicbuffer, a corrosion inhibitor, a wetting agent, and combinationsthereof; and (b) a second mixture comprising a source of peroxygen andwater, said second mixture optionally further comprising a hydrogenperoxide stabilizer.

In an additional aspect, a formulation is provided comprising (a) afirst mixture comprising a enzyme catalyst comprising the polypeptidehaving perhydrolysis activity described above and an acetylatedsaccharide selected from the group consisting of acetylatedmonosaccharides, acetylated disaccharides, acetylated polysaccharides,and combinations thereof, said first mixture optionally furthercomprising an inorganic or organic buffer, a corrosion inhibitor, and awetting agent; and (b) a second mixture comprising a source of peroxygenand water, said second mixture optionally comprising a hydrogen peroxidestabilizer.

In another aspect, an isolated polynucleotide encoding a Thermotogaacetyl xylan esterase polypeptide having perhydrolysis activity isprovided, wherein the polypeptide comprises the C-terminal conservedregion of SEQ ID NO: 31, provided that the polypeptide has asubstitution to amino acid 93 of SEQ ID NO: 31 selected from the groupconsisting of serine, threonine, valine, and alanine.

In a further aspect, an isolated Thermotoga acetyl xylan esterasepolypeptide is provided, wherein said polypeptide having perhydrolysisactivity and comprises the C-terminal conserved region of SEQ ID NO: 31,provided that the polypeptide has a substitution to amino acid 93 of SEQID NO: 31 selected from the group consisting of serine, threonine,valine, and alanine.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is CLUSTALW sequence comparison between acetyl xylan esterasesfrom Thermotoga neapolitana (SEQ ID NO: 32) and Thermotoga maritima MSB8(SEQ ID NO: 36).

FIG. 2 is a CLUSTALW sequence comparison between acetyl xylan esterasesfrom six Thermotoga species.

BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES

The following sequences comply with 37 C.F.R. §§1.821-1.825(“Requirements for patent applications Containing Nucleotide Sequencesand/or Amino Acid Sequence Disclosures—the Sequence Rules”) and areconsistent with World Intellectual Property Organization (WIPO) StandardST.25 (1998) and the sequence listing requirements of the EuropeanPatent Convention (EPC) and the Patent Cooperation Treaty (PCT) Rules5.2 and 49.5 (a-bis), and Section 208 and Annex C of the AdministrativeInstructions. The symbols and format used for nucleotide and amino acidsequence data comply with the rules set forth in 37 C.F.R. §1.822. SEQID NOs: 1, 2, 3, and 4 are nucleic acid sequences of variant acetylxylan esterase coding regions derived from the wild-type sequence of anacetyl xylan esterase from Thermotoga neapolitana.

SEQ ID NO: 5 represents the deduced amino acid sequence of the acetylxylan esterase variants derived from the wild-type sequence of an acetylxylan esterase from Thermotoga neapolitana, where the Xaa residue atposition 277 is Ala, Val, Ser, or Thr.

SEQ ID NOs: 6, 7, 8, and 9 are nucleic acid sequences of variant acetylxylan esterase coding regions derived from the wild-type sequence of anacetyl xylan esterase from Thermotoga maritima MSB8.

SEQ ID NO: 10 represents the deduced amino acid sequence of the acetylxylan esterase variants derived from the wild-type sequence of an acetylxylan esterase from Thermotoga maritima, where the Xaa residue atposition 277 is Ala, Val, Ser, or Thr.

SEQ ID NOs: 11, 12, 13, and 14 are nucleic acid sequences of variantacetyl xylan esterase coding regions derived from the wild-type sequenceof an acetyl xylan esterase from Thermotoga lettingae.

SEQ ID NO: 15 represents the deduced amino acid sequence of the acetylxylan esterase variants derived from the wild-type sequence of an acetylxylan esterase from Thermotoga petrophila, where the Xaa residue atposition 277 is Ala, Val, Ser, or Thr.

SEQ ID NOs: 16, 17, 18, and 19 are nucleic acid sequences of variantacetyl xylan esterase coding regions derived from the wild-type sequenceof an acetyl xylan esterase from Thermotoga petrophila.

SEQ ID NO: 20 represents the deduced amino acid sequences of the acetylxylan esterase variants derived from the wild-type sequence of an acetylxylan esterase from Thermotoga petrophila, where the Xaa residue atposition 277 is Ala, Val, Ser, or Thr.

SEQ ID NOs: 21, 22, 23, and 24 are nucleic acid sequences of one variantacetyl xylan esterase coding regions derived from the wild-type sequenceof an acetyl xylan esterase from Thermotoga sp. RQ2 described herein as“RQ2(a)”.

SEQ ID NO: 25 represents the deduced amino acid sequence of the acetylxylan esterase variants derived from the wild-type sequence of an acetylxylan esterase from Thermotoga sp. RQ2 described herein as “RQ2(a)”,where the Xaa residue at position 277 is Ala, Val, Ser, or Thr.

SEQ ID NOs: 26, 27, 28, and 29 are nucleic acid sequences of a secondvariant acetyl xylan esterase coding regions derived from Thermotoga sp.RQ2.

SEQ ID NO: 30 represents the deduced amino acid sequence of the acetylxylan esterase variants derived from the wild-type sequence of acetylxylan esterase from Thermotoga sp. RQ2 described herein as “RQ2(b)”,where the Xaa residue at position 278 is Ala, Val, Ser, or Thr.

SEQ ID NO: 31 represents a C-terminal conserved region of Thermotogaacetyl xylan esterases.

SEQ ID NO: 32 is an acetyl xylan esterase from Thermotoga neapolitana(GENBANK® accession # AAB70869).

SEQ ID NOs: 33 and 34 are primers described in Example 1.

SEQ ID NO: 35 is the amplified and codon optimized Thermotoganeapolitana nucleic acid product described in Example 1.

SEQ ID NO: 36 is an acetyl xylan esterase from Thermotoga maritime(GENBANK® accession # NP_(—)227893.1).

SEQ ID NO: 37 is the amplified Thermotoga maritime nucleic acid productdescribed in Example 10.

SEQ ID NOs: 38 and 39 are primers described in Example 10.

SEQ ID NO: 40 is the codon optimized sequence of a T. neapolitana acetylxylan esterase.

SEQ ID NO: 41 is the codon optimized sequence of a T, maritime acetylxylan esterase.

SEQ ID NOs: 42-193 are forward and reverse primers found in Table 1. SEQID NOs: 194-201 are forward and reverse primers found in Table 6.

SEQ ID NO: 202 is the deduced amino acid sequence of a Thermotogalettingae acetyl xylan esterase.

SEQ ID NO: 203 is the deduced amino acid sequence of a Thermotogapetrophila acetyl xylan esterase.

SEQ ID NO: 204 is the deduced amino acid sequence of a first acetylxylan esterase from Thermotoga sp. RQ2 described herein as “RQ2(a)”.

SEQ ID NO: 205 is the deduced amino acid sequence of a second acetylxylan esterase from Thermotoga sp. RQ2 described herein as “RQ2(b)”.

SEQ ID NOs: 206 and 207 are forward and reverse primer as described inExample 10.

SEQ NO: 208 is the nucleic acid sequence of the nucleic acid productamplified by SEQ ID NO: 206 and 207 that was used to prepare plasmidpSW207.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are variant enzymes that are structurally classified asCE-7 enzymes and have perhydrolysis activity. Also disclosed herein is aprocess for producing peroxycarboxylic acids from carboxylic acid estersusing the aforementioned variant enzymes as well as several processes ofusing the variants in disinfecting and laundry care applications.Further, disinfectant and/or laundry care formulations comprising theperoxycarboxylic acids produced by the processes described herein areprovided.

In this disclosure, a number of terms and abbreviations are used. Thefollowing definitions apply unless specifically stated otherwise.

As used herein, the articles “a”, “an”, and “the” preceding an elementor component of the invention are intended to be nonrestrictiveregarding the number of instances (i.e., occurrences) of the element orcomponent. Therefore “a”, “an” and “the” should be read to include oneor at least one, and the singular word form of the element or componentalso includes the plural unless the number is obviously meant to besingular.

As used herein, the term “comprising” means the presence of the statedfeatures, integers, steps, or components as referred to in the claims,but that it does not preclude the presence or addition of one or moreother features, integers, steps, components or groups thereof. The term“comprising” is intended to include embodiments encompassed by the terms“consisting essentially of” and “consisting of”. Similarly, the term“consisting essentially of” is intended to include embodimentsencompassed by the term “consisting of”.

As used herein, the term “about” modifying the quantity of an ingredientor reactant of the invention or employed refers to variation in thenumerical quantity that can occur, for example, through typicalmeasuring and liquid handling procedures used for making concentrates oruse solutions in the real world; through inadvertent error in theseprocedures; through differences in the manufacture, source, or purity ofthe ingredients employed to make the compositions or carry out themethods; and the like. The term “about” also encompasses amounts thatdiffer due to different equilibrium conditions for a compositionresulting from a particular initial mixture. Whether or not modified bythe term “about”, the claims include equivalents to the quantities.Where present, all ranges are inclusive and combinable. For example,when a range of “1 to 5” is recited, the recited range should beconstrued as including ranges “1 to 4”, “1 to 3”, “1-2”, “1-2 & 4-5”,“1-3 & 5”, and the like.

As used herein, the terms “substrate”, “suitable substrate”, and“carboxylic acid ester substrate” interchangeably refer specifically to:

-   -   (a) one or more esters having the structure

[X]_(m)R₅

-   -   wherein    -   X is an ester group of the formula R₆C(O)O;    -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl moiety,        optionally substituted with a hydroxyl group or C1 to C4 alkoxy        group, wherein R₆ optionally comprises one or more ether        linkages where R₆ is C2 to C7;    -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety        optionally substituted with a hydroxyl group, wherein each        carbon atom in R₅ individually comprises no more than one        hydroxyl group or no more than one ester group, and wherein R₅        optionally comprises one or more ether linkages;    -   m is 1 to the number of carbon atoms in R₅,    -   said one or more esters having a solubility in water of at least        5 ppm at 25° C.; or    -   (b) one or more glycerides having the structure

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₃ and R₄ are individually H or R₁C(O); or    -   (c) one or more esters of the formula

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₂ is a C1 to C10 straight chain or branched chain        alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkylheteroaryl,        heteroaryl,    -   (CH₂CH₂O)_(n), or (CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; or    -   (d) one or more acetylated monosaccharides, acetylated        disaccharides, or acetylated polysaccharides; or    -   (e) any combination of (a) through (d).

Examples of said carboxylic acid ester substrate may include monoacetin;triacetin; monopropionin; dipropionin; tripropionin; monobutyrin;dibutyrin; tributyrin; glucose pentaacetate; xylose tetraacetate;acetylated xylan; acetylated xylan fragments;β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal;tri-O-acetyl-glucal; propylene glycol diacetate; ethylene glycoldiacetate; monoesters or diesters of 1,2-ethanediol; 1,2-propanediol;1,3-propanediol; 1,2-butanediol; 1,3-butanediol; 2,3-butanediol,1,4-butanediol; 1,2-pentanediol; 2,5-pentanediol; 1,6-pentanediol,1,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; or any combinationthereof.

As used herein, the term “peracid” is synonymous with peroxyacid,peroxycarboxylic acid, peroxy acid, percarboxylic acid, and peroxoicacid.

As used herein, the term “peracetic acid” is abbreviated as “PAA” and issynonymous with peroxyacetic acid, ethaneperoxoic acid and all othersynonyms of CAS Registry Number 79-21-0.

As used herein, the term “monoacetin” is synonymous with glycerolmonoacetate, glycerin monoacetate, and glyceryl monoacetate.

As used herein, the term “diacetin” is synonymous with glyceroldiacetate; glycerin diacetate, glyceryl diacetate, and all othersynonyms of CAS Registry Number 25395-31-7.

As used herein, the term “triacetin” is synonymous with glycerintriacetate; glycerol triacetate; glyceryl triacetate,1,2,3-triacetoxypropane; 1,2,3-propanetriol triacetate and all othersynonyms of CAS Registry Number 102-76-1.

As used herein, the term “monobutyrin” is synonymous with glycerolmonobutyrate, glycerin monobutyrate, and glyceryl monobutyrate. As usedherein, the term “dibutyrin” is synonymous with glycerol dibutyrate andglyceryl dibutyrate.

As used herein, the term “tributyrin” is synonymous with glyceroltributyrate, 1,2,3-tributyrylglycerol, and all other synonyms of CASRegistry Number 60-01-5.

As used herein, the term “monopropionin” is synonymous with glycerolmonopropionate, glycerin monopropionate, and glyceryl monopropionate.

As used herein, the term “dipropionin” is synonymous with glyceroldipropionate and glyceryl dipropionate.

As used herein, the term “tripropionin” is synonymous with glyceryltripropionate, glycerol tripropionate, 1,2,3-tripropionylglycerol, andall other synonyms of CAS Registry Number 139-45-7.

As used herein, the term “ethyl acetate” is synonymous with aceticether, acetoxyethane, ethyl ethanoate, acetic acid ethyl ester, ethanoicacid ethyl ester, ethyl acetic ester and all other synonyms of CASRegistry Number 141-78-6.

As used herein, the term “ethyl lactate” is synonymous with lactic acidethyl ester and all other synonyms of CAS Registry Number 97-64-3.

As used herein, the terms “acetylated sugar” and “acetylated saccharide”refer to mono-, di- and polysaccharides comprising at least one acetylgroup. Examples include, but are not limited to, glucose pentaacetate;xylose tetraacetate; acetylated xylan; acetylated xylan fragments;β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal; andtri-O-acetyl-glucal.

As used herein, the terms “hydrocarbyl”, “hydrocarbyl group”, and“hydrocarbyl moiety” is meant a straight chain, branched or cyclicarrangement of carbon atoms connected by single, double, or triplecarbon to carbon bonds and/or by ether linkages, and substitutedaccordingly with hydrogen atoms. Such hydrocarbyl groups may bealiphatic and/or aromatic. Examples of hydrocarbyl groups includemethyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl,cyclobutyl, pentyl, cyclopentyl, methylcyclopentyl, hexyl, cyclohexyl,benzyl, and phenyl. In a preferred embodiment, the hydrocarbyl moiety isa straight chain, branched or cyclic arrangement of carbon atomsconnected by single carbon to carbon bonds and/or by ether linkages, andsubstituted accordingly with hydrogen atoms.

As used herein, the terms “monoesters” and “diesters” of 1,2-ethanediol;1,2-propanediol; 1,3-propanediol; 1,2-butanediol; 1,3-butanediol;2,3-butanediol; 1,4-butanediol; 1,2-pentanediol; 2,5-pentanediol;1,6-pentanediol; 1,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; andmixtures thereof, refer to said compounds comprising at least one estergroup of the formula RC(O)O, wherein R is a C1 to C7 linear hydrocarbylmoiety. In one embodiment, the carboxylic acid ester substrate isselected from the group consisting of propylene glycol diacetate (PGDA),ethylene glycol diacetate (EDGA), and mixtures thereof.

As used herein, the term “propylene glycol diacetate” is synonymous with1,2-diacetoxypropane, propylene diacetate, 1,2-propanediol diacetate,and all other synonyms of CAS Registry Number 623-84-7.

As used herein, the term “ethylene glycol diacetate” is synonymous with1,2-diacetoxyethane, ethylene diacetate, glycol diacetate, and all othersynonyms of CAS Registry Number 111-55-7.

As used herein, the terms “suitable enzymatic reaction mixture”,“components suitable for in situ generation of a peracid”, “suitablereaction components”, and “suitable aqueous reaction mixture” refer tothe materials and water in which the reactants and enzyme catalyst comeinto contact. The components of the suitable aqueous reaction mixtureare provided herein and those skilled in the art appreciate the range ofcomponent variations suitable for this process. In one embodiment, thesuitable enzymatic reaction mixture produces peroxycarboxylic acid insitu upon combining the reaction components. As such, the reactioncomponents may be provided as a multi-component system wherein one ormore of the reaction components remains separated until use. In anotherembodiment, the reaction components are first combined to form anaqueous solution of peroxycarboxylic acid which is subsequentlycontacted with the surface to be disinfected and/or bleached. The designof systems and means for separating and combining multiple activecomponents are known in the art and generally will depend upon thephysical form of the individual reaction components. For example,multiple active fluids (liquid-liquid) systems typically usemultichamber dispenser bottles or two-phase systems (e.g., U.S. PatentApplication Publication No. 2005/0139608; U.S. Pat. No. 5,398,846; U.S.Pat. No. 5,624,634; U.S. Pat. No. 6,391,840; E.P. Patent 0807156B1; U.S.Patent Application Publication No. 2005/0008526; and PCT Publication No.WO 00/61713A1) such as found in some bleaching applications wherein thedesired bleaching agent is produced upon mixing the reactive fluids.Other forms of multi-component systems used to generate peroxycarboxylicacid may include, but are not limited to those designed for one or moresolid components or combinations of solid-liquid components, such aspowders (e.g., U.S. Pat. No. 5,116,575), multi-layered tablets (e.g.,U.S. Pat. No. 6,210,639), water dissolvable packets having multiplecompartments (e.g., U.S. Pat. No. 6,995,125) and solid agglomerates thatreact upon the addition of water (e.g., U.S. Pat. No. 6,319,888). In oneembodiment, a multi-component formulation is provided as two individualcomponents whereby a peroxycarboxylic acid disinfectant is generatedupon combining the two components. In another embodiment, a formulationis provided comprising:

-   -   a) a first component comprising:        -   i) an enzyme powder as disclosed herein; and        -   ii) a carboxylic acid ester substrate, said first component            optionally comprising a further ingredient selected from the            group consisting of an inorganic or organic buffer, a            corrosion inhibitor, a wetting agent, and combinations            thereof; and    -   b) a second component comprising a source of peroxygen and        water, said second component optionally comprising a hydrogen        peroxide stabilizer.

In another embodiment, the carboxylic acid ester in the first mixture isselected from the group consisting of monoacetin, diacetin, triacetin,and combinations thereof. In another embodiment, the carboxylic acidester in the first mixture is an acetylated saccharide. In anotherembodiment, the enzyme catalyst in the first mixture is a particulatesolid. In another embodiment, the first reaction mixture is a solidtablet or powder.

As used herein, the term “perhydrolysis” is defined as the reaction of aselected substrate with peroxide to form a peroxycarboxylic acid.Typically, inorganic peroxide is reacted with the selected substrate inthe presence of a catalyst to produce the peroxycarboxylic acid. As usedherein, the term “chemical perhydrolysis” includes perhydrolysisreactions in which a substrate (a peroxycarboxylic acid precursor) iscombined with a source of hydrogen peroxide wherein peroxycarboxylicacid is formed in the absence of an enzyme catalyst.

As used herein, the terms “perhydrolase specific activity” or“perhydrolase activity” refer to the catalyst activity per unit mass(for example, milligram) of protein, dry cell weight, or immobilizedcatalyst weight.

As used herein, “one unit of enzyme activity” or “one unit of activity”or “U” is defined as the amount of perhydrolase activity required forthe production of 1 μmol of peroxycarboxylic acid product per minute ata specified temperature.

As used herein, the terms “enzyme catalyst” and “perhydrolase catalyst”refer to a catalyst comprising an enzyme having perhydrolysis activityand may be in the form of a whole microbial cell, permeabilizedmicrobial cell(s), one or more cell components of a microbial cellextract, partially purified enzyme, or purified enzyme. The enzymecatalyst may also be chemically modified (e.g., by pegylation or byreaction with cross-linking reagents). The perhydrolase catalyst mayalso be immobilized on a soluble or insoluble support using methodswell-known to those skilled in the art; see for example, Immobilizationof Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press,Totowa, N.J., USA; 1997. As described herein, all of the present enzymeshaving perhydrolysis activity are structurally members of thecarbohydrate family esterase family 7 (CE-7 family) of enzymes (seeCoutinho, P. M., Henrissat, B. “Carbohydrate-active enzymes: anintegrated database approach” in Recent Advances in CarbohydrateBioendineering, H. J. Gilbert, G. Davies, B. Henrissat and B. Svenssoneds., (1999) The Royal Society of Chemistry, Cambridge, pp. 3-12.). TheCE-7 family of enzymes has been demonstrated to be particularlyeffective for producing peroxycarboxylic acids from a variety ofcarboxylic acid ester substrates when combined with a source ofperoxygen (See PCT publication No. WO2007/070609 and U.S. PatentApplication Publication Nos. 200810176299, 20081176783, and 200910005590to DiCosimo et al.; each herein incorporated by reference in theirentireties). The CE-7 enzyme family includes cephalosporin Cdeacetylases (CAHs; E.C. 3.1.1.41) and acetyl xylan esterases (AXEs;E.C. 3.1.1.72). Members of the CE-7 enzyme family share a conservedsignature motif (Vincent et at, J. Mol. Biol., 330:593-606 (2003)).

As used herein, the terms “signature motif”, “CE-7 signature motif”, and“diagnostic motif” refer to conserved structures shared among a familyof enzymes having a defined activity. The signature motif can be used todefine and/or identify the family of structurally related enzymes havingsimilar enzymatic activity for a defined family of substrates. Thesignature motif can be a single contiguous amino acid sequence or acollection of discontiguous, conserved motifs that together form thesignature motif. Typically, the conserved motif(s) is represented by anamino acid sequence. The present variant enzymes having perhydrolysisactivity (“perhydrolases”) belong to the family of CE-7 carbohydrateesterases (i.e., all of the present variants retain the CE-7 signaturemotif).

As used herein, “structurally classified as a CE-7 enzyme”,“structurally classified as a carbohydrate esterase family 7 enzyme”,“structurally classified as a CE-7 carbohydrate esterase”, and “CE-7perhydrolase” will be used to refer to enzymes having perhydrolysisactivity that are structurally classified as a CE-7 carbohydrateesterase based on the presence of the CE-7 signature motif (Vincent etal., supra). The “signature motif” for CE-7 esterases comprises threeconserved motifs (residue position numbering relative to referencesequence SEQ ID NO: 32):

a) Arg118-Gly119-Gln120;

b) Gly179-Xaa180-Ser181-Gln182-Gly183; and

c) His298-Glu299.

Typically, the Xaa at amino acid residue position 180 is glycine,alanine, proline, tryptophan, or threonine. Two of the three amino acidresidues belonging to the catalytic triad are in bold. In oneembodiment, the Xaa at amino acid residue position 180 is selected fromthe group consisting of glycine, alanine, proline, tryptophan, andthreonine.

Further analysis of the conserved motifs within the CE-7 carbohydrateesterase family indicates the presence of an additional conserved motif(LXD at amino acid positions 267-269 of SEQ ID NO: 32) that may be usedto further define a member of the CE-7 carbohydrate esterase family. Ina further embodiment, the signature motif defined above includes afourth conserved motif defined as:

Leu267-Xaa268-Asp269.

The Xaa at amino acid residue position 268 is typically isoleucine,valine, or methionine. The fourth motif includes the aspartic acidresidue (bold) belonging to the catalytic triad (Ser181-Asp269-His298).

The conserved motifs found with CE-7 perhydrolases from several wildtype Thermotoga species.

TABLE A Conserved motifs found within the enzymes having perhydrolaseactivity. Perhydrolase RGQ motif^(a) GXSQG motif^(a) LXD motif^(b) HEmotif^(a) Sequence (Residue #s) (Residue #s) (Residue #s) (Residue #s)SEQ ID NO: 32 118-120 186-190 272-274 303-304 SEQ ID NO: 36 118-120186-190 272-274 303-304 SEQ ID NO: 202 118-120 186-190 272-274 303-304SEQ ID NO: 203 118-120 186-190 272-274 303-304 SEQ ID NO. 204 118-120186-190 272-274 303-304 SEQ ID NO. 205 119-121 187-191 273-275 304-305^(a)= Conserved motifs defined by Vincent et al., supra used to definethe signature motif. ^(b)= an additional motif that may be useful infurther defining the signature motif defined by Vincent et al., supra.

As used herein, the terms “cephalosporin C deacetylase” and“cephalosporin C acetyl hydrolase” refer to an enzyme (E.C. 3.1.1.41)that catalyzes the deacetylation of cephalosporins such as cephalosporinC and 7-aminocephalosporanic acid (Mitsushima et at, (1995) Appl. Env.Microbiol. 61(6):2224-2229).

As used herein, “acetyl xylan esterases” refers to an enzyme (E.C.3.1.172; AXEs) that catalyzes the deacetylation of acetylated xylans andother acetylated saccharides.

As used herein, the term “Thermotoga neapolitana” refers to a strain ofThermotoga neapolitana reported to have acetyl xylan esterase activity(GENBANK® AAB70869). The amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga neapolitana is provided as SEQ IDNO: 32.

As used herein, the term “Thermotoga maritima” refers to a bacterialcell reported to have acetyl xylan esterase activity(GENBANK®NP_(—)227893.1). The amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga maritima is provided as SEQ ID NO:36. As used herein, the term “Thermotoga lettingae” refers to abacterial cell reported to have acetyl xylan esterase activity(GENBANK®CP000812). The deduced amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga lettingae is provided as SEQ IDNO: 202.

As used herein, the term “Thermotoga petrophila” refers to a bacterialcell reported to have acetyl xylan esterase activity (GEN BANK®CP000702). The deduced amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga lettingae is provided as SEQ IDNO: 203.

As used herein, the term “Thermotoga sp. RQ2” refers to a bacterial cellreported to have acetyl xylan esterase activity (GEN BANK® CP000969).Two different acetyl xylan esterases have been identified fromThermotoga sp. RQ2 and are referred to herein as “RQ2(a)” (the deducedamino acid sequence provided as SEQ ID NO: 204) and “RQ2(b)” (thededuced amino acid sequence provided as SEQ ID NO: 205).

As used herein, an “isolated nucleic acid molecule” and “isolatednucleic acid fragment” will be used interchangeably and refer to apolymer of RNA or DNA that is single- or double-stranded, optionallycontaining synthetic, non-natural or altered nucleotide bases. Anisolated nucleic acid molecule in the form of a polymer of DNA may becomprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

The term “amino acid” refers to the basic chemical structural unit of aprotein or polypeptide. The following abbreviations are used herein toidentify specific amino acids:

Three-Letter One-Letter Amino Acid Abbreviation Abbreviation Alanine AlaA Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys CGlutamine Gln Q Glutamic acid Glu E Glycine Gly G Histidine His HIsoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met MPhenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr TTryptophan Trp W Tyrosine Tyr Y Valine Val V Any amino acid or asdefined herein Xaa X

As used herein, “substantially similar” refers to nucleic acid moleculeswherein changes in one or more nucleotide bases results in the addition,substitution, or deletion of one or more amino acids, but does notaffect the functional properties (i.e., perhydrolytic activity) of theprotein encoded by the DNA sequence. As used herein, “substantiallysimilar” also refers to an enzyme having an amino acid sequence that isat least 40%, preferably at least 50%, more preferably at least 60%,more preferably at least 70%, even more preferably at least 80%, yeteven more preferably at least 90%, and most preferably at least 95%identical to the sequences reported herein wherein the resulting enzymeretains the present functional properties (i.e., perhydrolyticactivity). “Substantially similar” may also refer to an enzyme havingperhydrolytic activity encoded by nucleic acid molecules that hybridizesunder stringent conditions to the nucleic acid molecules reportedherein. It is therefore understood that the invention encompasses morethan the specific exemplary sequences.

For example, it is well known in the art that alterations in a genewhich result in the production of a chemically equivalent amino acid ata given site, but do not affect the functional properties of the encodedprotein are common. For the purposes of the present inventionsubstitutions are defined as exchanges within one of the following fivegroups:

-   -   1. Small aliphatic, nonpolar or slightly polar residues: Ala,        Ser, Thr (Pro, Gly);    -   2. Polar, negatively charged residues and their amides: Asp,        Asn, Glu, Gln;    -   3. Polar, positively charged residues: His, Arg, Lys;    -   4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val (Cys);        and    -   5. Large aromatic residues: Phe, Tyr, and Trp.        Thus, a codon for the amino acid alanine, a hydrophobic amino        acid, may be substituted by a codon encoding another less        hydrophobic residue (such as glycine) or a more hydrophobic        residue (such as valine, leucine, or isoleucine). Similarly,        changes which result in substitution of one negatively charged        residue for another (such as aspartic acid for glutamic acid) or        one positively charged residue for another (such as lysine for        arginine) can also be expected to produce a functionally        equivalent product. In many cases, nucleotide changes which        result in alteration of the N-terminal and C-terminal portions        of the protein molecule would also not be expected to alter the        activity of the protein.

Each of the proposed modifications is well within the routine skill inthe art, as is determination of retention of biological activity of theencoded products. Moreover, the skilled artisan recognizes thatsubstantially similar sequences are encompassed by the presentinvention. In one embodiment, substantially similar sequences aredefined by their ability to hybridize, under stringent conditions(0.1×SSC, 0.1% SDS, 65° C. and washed with 2×SSC, 0.1% SDS followed by0.1×SSC, 0.1% SDS, 65° C.) with the sequences exemplified herein.

As used herein, a nucleic acid molecule is “hybridizable” to anothernucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when asingle strand of the first molecule can anneal to the other moleculeunder appropriate conditions of temperature and solution ionic strength.Hybridization and washing conditions are well known and exemplified inSambrook, J. and Russell, D., T. Molecular Cloning: A Laboratory Manual,Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor(2001). The conditions of temperature and ionic strength determine the“stringency” of the hybridization. Stringency conditions can be adjustedto screen for moderately similar molecules, such as homologous sequencesfrom distantly related organisms, to highly similar molecules, such asgenes that duplicate functional enzymes from closely related organisms.Post-hybridization washes typically determine stringency conditions. Oneset of preferred conditions uses a series of washes starting with 6×SSC,0.5% SDS at room temperature for 15 min, then repeated with 2×SSC, 0.5%SDS at 45° C. for 30 min, and then repeated twice with 0.2×SSC, 0.5% SDSat 50° C. for 30 min. A more preferred set of conditions uses highertemperatures in which the washes are identical to those above except forthe temperature of the final two 30 min washes in 0.2×SSC, 0.5% SDS wasincreased to 60° C. Another preferred set of stringent hybridizationconditions is 0.1×SSC, 0.1% SDS, 65° C. and washed with 2×SSC, 0.1% SDSfollowed by a final wash of 0.1×SSC, 0.1% SDS, 65° C. with the sequencesexemplified herein.

Hybridization requires that the two nucleic acids contain complementarysequences, although depending on the stringency of the hybridization,mismatches between bases are possible. The appropriate stringency forhybridizing nucleic acids depends on the length of the nucleic acids andthe degree of complementation, variables well known in the art. Thegreater the degree of similarity or homology between two nucleotidesequences, the greater the value of Tm for hybrids of nucleic acidshaving those sequences. The relative stability (corresponding to higherTm) of nucleic acid hybridizations decreases in the following order:RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotidesin length, equations for calculating Tm have been derived (Sambrook andRussell, supra). For hybridizations with shorter nucleic acids, i.e.,oligonucleotides, the position of mismatches becomes more important, andthe length of the oligonucleotide determines its specificity (Sambrookand Russell, supra). In one aspect, the length for a hybridizablenucleic acid is at least about 10 nucleotides. Preferably, a minimumlength for a hybridizable nucleic acid is at least about 15 nucleotidesin length, more preferably at least about 20 nucleotides in length, evenmore preferably at least 30 nucleotides in length, even more preferablyat least 300 nucleotides in length, and most preferably at least 800nucleotides in length. Furthermore, the skilled artisan will recognizethat the temperature and wash solution salt concentration may beadjusted as necessary according to factors such as length of the probe.

As used herein, the term “percent identity” is a relationship betweentwo or more polypeptide sequences or two or more polynucleotidesequences, as determined by comparing the sequences. In the art,“identity” also means the degree of sequence relatedness betweenpolypeptide or polynucleotide sequences, as the case may be, asdetermined by the match between strings of such sequences. “Identity”and “similarity” can be readily calculated by known methods, includingbut not limited to those described in: Computational Molecular Biology(Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputing:Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, NY(1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M., andGriffin, H. G., eds.) Humana Press, NJ (1994); Sequence Analysis inMolecular Biology (von Heinje, G., ed.) Academic Press (1987); andSequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) StocktonPress, NY (1991). Methods to determine identity and similarity arecodified in publicly available computer programs. Sequence alignmentsand percent identity calculations may be performed using the Megalignprogram of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,Madison, Wis.), the AlignX program of Vector NTI v. 7.0 (Informax, Inc.,Bethesda, Md.), or the EMBOSS Open Software Suite (EMBL-EBI; Rice etal., Trends in Genetics 16, (6):276-277 (2000)). Multiple alignment ofthe sequences can be performed using the Clustal method (i.e. CLUSTALW;for example version 1.83) of alignment (Higgins and Sharp, CABIOS,5:151-153 (1989); Higgins et al., Nucleic Acids Res. 22:4673-4680(1994); and Chema et al., Nucleic Acids Res 31 (13):3497-500 (2003)),available from the European Molecular Biology Laboratory via theEuropean Bioinformatics Institute) with the default parameters. Suitableparameters for CLUSTALW protein alignments include GAP Existencepenalty=15, GAP extension=0.2, matrix=Gonnet (e.g. Gonnet250), proteinENDGAP=−1, Protein GAPDIST=4, and KTUPLE=1. In one embodiment, a fast orslow alignment is used with the default settings where a slow alignmentis preferred. Alternatively, the parameters using the CLUSTALW method(version 1.83) may be modified to also use KTUPLE=1, GAP PENALTY=10, GAPextension=1, matrix=BLOSUM (e.g. BLOSUM64), WINDOW=5, and TOP DIAGONALSSAVED=5.

In one aspect of the present invention, suitable isolated nucleic acidmolecules (isolated polynucleotides of the present invention) encode apolypeptide having an amino acid sequence that is at least about 50%,preferably at least 60%, more preferably at least 70%, more preferablyat least 80%, even more preferably at least 85%, even more preferably atleast 90%, and most preferably at least 95% identical to the amino acidsequences reported herein. Suitable nucleic acid molecules of thepresent invention not only have the above homologies, but also typicallyencode a polypeptide having about 300 to about 340 amino acids, morepreferably about 310 to about 330 amino acids, and most preferably about325 amino acids.

As used herein, “codon degeneracy” refers to the nature of the geneticcode permitting variation of the nucleotide sequence without affectingthe amino acid sequence of an encoded polypeptide. Accordingly, thepresent invention relates to any nucleic acid molecule that encodes allor a substantial portion of the amino acid sequences encoding thepresent microbial polypeptide. The skilled artisan is well aware of the“codon-bias” exhibited by a specific host cell in usage of nucleotidecodons to specify a given amino acid. Therefore, when synthesizing agene for improved expression in a host cell, it is desirable to designthe gene such that its frequency of codon usage approaches the frequencyof preferred codon usage of the host cell.

As used herein, the term “codon optimized” as it refers to genes orcoding regions of nucleic acid molecules for transformation of varioushosts, refers to the alteration of codons in the gene or coding regionsof the nucleic acid molecules to reflect the typical codon usage of thehost organism without altering the polypeptide for which the DNA codes.

As used herein, “synthetic genes” can be assembled from oligonucleotidebuilding blocks that are chemically synthesized using procedures knownto those skilled in the art. These building blocks are ligated andannealed to form gene segments that are then enzymatically assembled toconstruct the entire gene. “Chemically synthesized”, as pertaining to aDNA sequence, means that the component nucleotides were assembled invitro. Manual chemical synthesis of DNA may be accomplished usingwell-established procedures, or automated chemical synthesis can beperformed using one of a number of commercially available machines.Accordingly, the genes can be tailored for optimal gene expression basedon optimization of nucleotide sequences to reflect the codon bias of thehost cell. The skilled artisan appreciates the likelihood of successfulgene expression if codon usage is biased towards those codons favored bythe host. Determination of preferred codons can be based on a survey ofgenes derived from the host cell where sequence information isavailable.

As used herein, “gene” refers to a nucleic acid molecule that expressesa specific protein, including regulatory sequences preceding (5′non-coding sequences) and following (3′ non-coding sequences) the codingsequence. “Native gene” refers to a gene as found in nature with its ownregulatory sequences. “Chimeric gene” refers to any gene that is not anative gene, comprising regulatory and coding sequences that are notfound together in nature. Accordingly, a chimeric gene may compriseregulatory sequences and coding sequences that are derived fromdifferent sources, or regulatory sequences and coding sequences derivedfrom the same source, but arranged in a manner different from that foundin nature. “Endogenous gene” refers to a native gene in its naturallocation in the genome of an organism. A “foreign” gene refers to a genenot normally found in the host organism, but that is introduced into thehost organism by gene transfer. Foreign genes can comprise native genesinserted into a non-native organism, or chimeric genes. A “transgene” isa gene that has been introduced into the genome by a transformationprocedure.

As used herein, “coding sequence” refers to a DNA sequence that codesfor a specific amino acid sequence. “Suitable regulatory sequences”refer to nucleotide sequences located upstream (5′ non-codingsequences), within, or downstream (3′ non-coding sequences) of a codingsequence, and which influence the transcription, RNA processing orstability, or translation of the associated coding sequence. Regulatorysequences may include promoters, translation leader sequences, RNAprocessing site, effector binding site and stem-loop structure.

As used herein, “promoter” refers to a DNA sequence capable ofcontrolling the expression of a coding sequence or functional RNA. Ingeneral, a coding sequence is located 3′ to a promoter sequence.Promoters may be derived in their entirety from a native gene, or becomposed of different elements derived from different promoters found innature, or even comprise synthetic DNA segments. It is understood bythose skilled in the art that different promoters may direct theexpression of a gene at different stages of development, or in responseto different environmental or physiological conditions. Promoters thatcause a gene to be expressed at most times are commonly referred to as“constitutive promoters”. It is further recognized that since in mostcases the exact boundaries of regulatory sequences have not beencompletely defined, DNA fragments of different lengths may haveidentical promoter activity.

As used herein, the “3′ non-coding sequences” refer to DNA sequenceslocated downstream of a coding sequence and include polyadenylationrecognition sequences (normally limited to eukaryotes) and othersequences encoding regulatory signals capable of affecting mRNAprocessing or gene expression. The polyadenylation signal is usuallycharacterized by affecting the addition of polyadenylic acid tracts(normally limited to eukaryotes) to the 3′ end of the mRNA precursor.

As used herein, the term “operably linked” refers to the association ofnucleic acid sequences on a single nucleic acid molecule so that thefunction of one is affected by the other. For example, a promoter isoperably linked with a coding sequence when it is capable of affectingthe expression of that coding sequence, i.e., that the coding sequenceis under the transcriptional control of the promoter. Coding sequencescan be operably linked to regulatory sequences in sense or antisenseorientation.

As used herein, the term “expression” refers to the transcription andstable accumulation of sense (mRNA) or antisense RNA derived from thenucleic acid molecule of the invention. Expression may also refer totranslation of mRNA into a polypeptide.

As used herein, “transformation” refers to the transfer of a nucleicacid molecule into the genome of a host organism, resulting ingenetically stable inheritance. In the present invention, the hostcell's genome includes chromosomal and extrachromosomal (e.g. plasmid)genes. Host organisms containing the transformed nucleic acid moleculesare referred to as “transgenic” or “recombinant” or “transformed”organisms.

As used herein, the terms “plasmid”, “vector” and “cassette” refer to anextrachromosomal element often carrying genes which are not part of thecentral metabolism of the cell, and usually in the form of circulardouble-stranded DNA molecules. Such elements may be autonomouslyreplicating sequences, genome integrating sequences, phage or nucleotidesequences, linear or circular, of a single- or double-stranded DNA orRNA, derived from any source, in which a number of nucleotide sequenceshave been joined or recombined into a unique construction which iscapable of introducing a promoter fragment and DNA sequence for aselected gene product along with appropriate 3′ untranslated sequenceinto a cell “Transformation cassette” refers to a specific vectorcontaining a foreign gene and having elements in addition to the foreigngene that facilitate transformation of a particular host cell.“Expression cassette” refers to a specific vector containing a foreigngene and having elements in addition to the foreign gene that allow forenhanced expression of that gene in a foreign host.

As used herein, the term “sequence analysis software” refers to anycomputer algorithm or software program that is useful for the analysisof nucleotide or amino acid sequences. “Sequence analysis software” maybe commercially available or independently developed. Typical sequenceanalysis software will include, but is not limited to, the GCG suite ofprograms (Wisconsin Package Version 9.0, Genetics Computer Group (GCG),Madison, Wis.), BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol.215:403-410 (1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison,Wis. 53715 USA), CLUSTALW (for example, version 1.83; Thompson et al.,Nucleic Acids Research, 22(22):4673-4680 (1994), and the FASTA programincorporating the Smith-Waterman algorithm (W. R. Pearson, Comput.Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992,111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, N.Y.),Vector NTI (Informax, Bethesda, Md.) and Sequencher v. 4.05. Within thecontext of this application it will be understood that where sequenceanalysis software is used for analysis, that the results of the analysiswill be based on the “default values” of the program referenced, unlessotherwise specified. As used herein “default values” will mean any setof values or parameters set by the software manufacturer that originallyload with the software when first initialized.

As used herein, the term “biological contaminants” refers to one or moreunwanted and/or pathogenic biological entities including, but notlimited to, microorganisms, spores, viruses, prions, and mixturesthereof. Processes disclosed herein produce an efficacious concentrationof at least one percarboxylic acid useful to reduce and/or eliminate thepresence of the viable biological contaminants. In a preferredembodiment, the biological contaminant is a viable pathogenicmicroorganism.

As used herein, the term “disinfect” refers to the process ofdestruction of or prevention of the growth of biological contaminants.As used herein, the term “disinfectant” refers to an agent thatdisinfects by destroying, neutralizing, or inhibiting the growth ofbiological contaminants. Typically, disinfectants are used to treatinanimate objects or surfaces. As used herein, the term “disinfection”refers to the act or process of disinfecting. As used herein, the term“antiseptic” refers to a chemical agent that inhibits the growth ofdisease-carrying microorganisms. In one aspect, the biologicalcontaminants are pathogenic microorganisms.

As used herein, the term “sanitary” means of or relating to therestoration or preservation of health, typically by removing, preventingor controlling an agent that may be injurious to health. As used herein,the term “sanitize” means to make sanitary. As used herein, the term“sanitize” refers to a sanitizing agent. As used herein the term“sanitization” refers to the act or process of sanitizing.

As used herein, the term “virucide” refers to an agent that inhibits ordestroys viruses, and is synonymous with “viricide”. An agent thatexhibits the ability to inhibit or destroy viruses is described ashaving “virucidal” activity. Peracids can have virucidal activity.Typical alternative virucides known in the art which may be suitable foruse with the present invention include, for example, alcohols, ethers,chloroform, formaldehyde, phenols, beta propiolactone, iodine, chlorine,mercury salts, hydroxylamine, ethylene oxide, ethylene glycol,quaternary ammonium compounds, enzymes, and detergents.

As used herein, the term “biocide” refers to a chemical agent, typicallybroad spectrum, which inactivates or destroys microorganisms. A chemicalagent that exhibits the ability to inactivate or destroy microorganismsis described as having “biocidal” activity. Peracids can have biocidalactivity. Typical alternative biocides known in the art, which may besuitable for use in the present invention include, for example,chlorine, chlorine dioxide, chloroisocyanurates, hypochlorites, ozone,acrolein, amines, chlorinated phenolics, copper salts, organo-sulphurcompounds, and quaternary ammonium salts.

As used herein, the phrase “minimum biocidal concentration” refers tothe minimum concentration of a biocidal agent that, for a specificcontact time, will produce a desired lethal, irreversible reduction inthe viable population of the targeted microorganisms. The effectivenesscan be measured by the log₁₀ reduction in viable microorganisms aftertreatment. In one aspect, the targeted reduction in viablemicroorganisms after treatment is at least a 3-log reduction, morepreferably at least a 4-log reduction, and most preferably at least a5-log reduction. In another aspect, the minimum biocidal concentrationis at least a 6-log reduction in viable microbial cells.

As used herein, the terms “peroxygen source” and “source of peroxygen”refer to compounds capable of providing hydrogen peroxide at aconcentration of about 1 mM or more when in an aqueous solutionincluding, but not limited to hydrogen peroxide, hydrogen peroxideadducts (e.g., urea-hydrogen peroxide adduct (carbamide peroxide)),perborates, and percarbonates. As described herein, the concentration ofthe hydrogen peroxide provided by the peroxygen compound in the aqueousreaction formulation is initially at least 1 mM or more upon combiningthe reaction components. In one embodiment, the hydrogen peroxideconcentration in the aqueous reaction formulation is at least 10 mM. Inanother embodiment, the hydrogen peroxide concentration in the aqueousreaction formulation is at least 100 mM. In another embodiment, thehydrogen peroxide concentration in the aqueous reaction formulation isat least 200 mM. In another embodiment, the hydrogen peroxideconcentration in the aqueous reaction formulation is 500 mM or more. Inyet another embodiment, the hydrogen peroxide concentration in theaqueous reaction formulation is 1000 mM or more. The molar ratio of thehydrogen peroxide to enzyme substrate, e.g. triglyceride,(H₂O₂:substrate) in the aqueous reaction formulation may be from about0.002 to 20, preferably about 0.1 to 10, and most preferably about 0.5to 5.

Polypeptide Variants Having Perhydrolysis Activity and BeingStructurally Classified as CE-7 Enzymes

An object of this invention is to provide perhydrolases with improvedactivity for production of an efficacious concentration of percarboxylicacid for disinfection (e.g., for inactivation of bacteria, viruses, andspores), relative to the wild-type enzymes from which they were derived.A second object of this invention is to provide perhydrolases withimproved activity across the entire pH range of activity relative to thewild-type enzymes, where improvement in specific activity results in adecrease in the amount of enzyme required to produce an efficaciousconcentration of peroxycarboxylic acid (and a concomitant decrease inenzyme cost in a formulation). A third object of the present inventionis to provide perhydrolases with an improved perhydrolysis/hydrolysisratio (P/H ratio) relative to the wild-type enzymes.

The X-ray crystal structure for T. maritima CE-7 acetyl xylan esterasehas been published (see the Research Collaboratory for StructuralBioinformatics (RCSB) protein databank). The amino acid sequence of T.neapolitana CE-7 perhydrolase has 91% identity to the T. maritima acetylxylan esterase, allowing it to be mapped to the T. maritima X-raycrystal structure. In addition to the canonical catalytic triad (H303,S188, and D274), several residues are also within the active site of T.neapolitana, and substitutions at these sites were chosen to determineif the resulting variant enzymes had beneficial changes in the pKa ofthe active site, and in the overall K_(cat) and K_(m) for substrates,and for improvement in the perhydrolysis/hydrolysis ratio (P/H ratio)relative to the wild-type enzymes. Based on the observed perhydrolysisactivity, a series of variant CE-7 enzymes having increased peraceticacid generation activity, with respect to the wild-type CE-7 enzymes,were created.

The process of improving perhydrolysis activity involves construction ofan expression vector comprising the nucleotide sequence encoding apolypeptide that is structurally classified as a CE-7 enzyme,mutagenesis of the enzyme coding sequence, and finally isolation ofvariants with increased peracetic acid generation activity. Typically,the approach involves the creating and isolating variant enzymes whichincrease peracetic acid generation activity in the presence of acetate,triacetin, and hydrogen peroxide. Subsequent rounds of mutagenesis, ifdesired, allow for evolution of the enzyme-coding sequence.

Mutant enzyme libraries can be prepared using any wild-type (orsubstantially similar) nucleotide sequence encoding a polypeptide thatis structurally classified as a CE-7 enzyme as the starting material formutagenesis. Methods for mutating sequences are well established in theliterature. For example, in vitro mutagenesis and selection,site-directed mutagenesis, error prone PCR (Melnikov et. al., NucleicAcids Res. 27(4):1056-62 (1999)), “gene shuffling” or other means can beemployed to obtain mutations of enzyme sequences. This could permitproduction of a polypeptide having, for example, improved activity at anacidic pH for production of a percarboxylic acid for disinfectionrelative to the wild-type enzyme, improved activity across the entire pHrange of activity relative to the wild-type enzymes, and/or improved P/Hratio relative to the wild-type enzyme.

If desired, the regions of an enzyme important for enzymatic activitycan be determined through routine site-directed mutagenesis, expressionof the resulting variant polypeptides, and determination of theiractivities. Mutants may include deletions, insertions and pointmutations, or combinations thereof.

As discussed in the Examples below, a key cysteine residue has beenidentified in Thermotoga acetyl xylan esterases that, when altered to analanine, valine, serine, or threonine, unexpectedly increasesperhydrolysis activity of the variant polypeptide as compared to thewild-type acetyl xylan esterase lacking the specified amino acidsubstitution. Because of the high homology between acetyl xylanesterases across the Thermotoga genus, it is expected that asubstitution of this cysteine with an alanine, valine, serine, orthreonine in any Thermotoga genus will produce similar results as thatdescribed in the working examples. Thus, in some embodiments, thevariant polypeptides and the polynucleotides that encode suchpolypeptides are derived from wild-type Thermotoga acetyl xylanesterases having perhydrolysis activity, where the Thermotoga acetylxylan esterase comprises the C-terminal region as set forth in SEQ IDNO: 31, with the variant polypeptide having an alanine, valine, serine,or threonine residue in place of the cysteine residue at amino acidposition 93 of SEQ ID NO: 31. The C-terminal region set forth in SEQ IDNO: 31 is highly conserved among Thermotoga acetyl xylan esterases (seeFIG. 2 for alignment between six acetyl xylan esterases) and thus canserve as an identifier of acetyl xylan esterases that are amenable tomutation of the key cysteine residue disclosed herein.

Even though several residues in SEQ ID NO: 31 are noted as “any”residues, there are typical amino acids that appear at many of theseresidues. For example, typical amino acids at positions marked Xaa inSEQ ID NO: 31 are glycine at position 2, serine at position 13, lysineat position 18, lysine at position 20, leucine at position 23, cysteineat position 24, aspartic acid at position 25, phenylalanine at position32, arginine at position 33, leucine at position 38, valine or threonineat position 39, threonine at position 41, histidine at position 42,alanine at position 45, threonine at position 48, asparagine at position49, phenylalanine or tyrosine at position 50, leucine at position 51,threonine at position 53, arginine at position 55, glutamic acid atposition 58, isoleucine at position 60, alanine or valine at position75, isoleucine at position 79, glycine at position 86, arginine atposition 90, isoleucine at position 91, histidine or tyrosine atposition 104, praline at position 108, glutamic acid at position 110,arginine at position 112, isoleucine at position 113, tyrosine atposition 116, arginine at position 118, glycine at position 123,glutamine at position 126, alanine at position 127, isoleucine atposition 128, glutamine at position 130, valine or leucine at position131, lysine at position 132, leucine at position 134, and arginine orlysine at position 136.

Addition and/or deletion of one or more amino acids in the Thermotogaacetyl xylan esterase C-terminal region are permitted so long as suchaddition(s) and/or deletion(s) does not affect the functional propertiesof the enzyme.

In more specific embodiments, the variant polypeptides disclosed hereinhave at least 95% amino acid sequence identity (or, in variousembodiments, 96%, 97%, 98%, or 99% sequence identity), based, forexample, on the CLUSTAL method of alignment with pairwise alignmentdefault parameters of KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALSSAVED=5, when compared to

-   -   (a) SEQ ID NOs: 5, 10, 15, 20, or 25, provided that a        substitution to amino acid 277 of SEQ ID NOs: 5, 10, 15, 20, or        25 is selected from the group consisting of serine, threonine,        valine, and alanine; or    -   (b) SEQ ID NO:30, provided that a substitution to amino acid 278        of SEQ ID NO:30 is selected from the group consisting of serine,        threonine, valine, and alanine.

Even more specifically, the variant polypeptide having improvedperhydrolytic activity (perhydrolytic activity and/or an increase in theP/H ratio) comprises SEQ ID NOs: 5, 10, 15, 20, 25, or 30. In anotherembodiment, the variant polypeptide comprises an amino acid sequenceselected from the group consisting of SEQ ID NOs: 5, 10, 15, 20, 25, and30 wherein Xaa in each respective sequence is selected from the groupconsisting of alanine, serine, threonine, and valine. In a furtherembodiment, the variant polypeptide comprises an amino acid sequenceselected from the group consisting of SEQ ID NOs: 5 and 10, wherein Xaain each respective sequence is selected from the group consisting ofalanine, serine, threonine, and valine.

Protein Engineering

The present CE-7 esterase variants were produced by mutagenesis. It iscontemplated that the present nucleotides may be used to produce geneproducts having further enhanced or altered activity. Various methodsare known for mutating a native gene sequence to produce a gene productwith altered or enhanced activity including, but not limited to 1)random mutagenesis, 2) domain swapping (using zinc finger domains orrestriction enzymes, 3) error-prone PCR (Melnikov at al., Nucleic AcidsResearch 27(4):1056-1062 (1999)); 4) site directed mutagenesis (Coombsat al., Proteins (1998), pp 259-311, 1 plate. Angeletti, Ruth Hogue,Ed., Academic: San Diego, Calif.); and 5) “gene shuffling” (U.S. Pat.Nos. 5,605,793; 5,811,238; 5,830,721; and 5,837,458, incorporated hereinby reference).

The polymerase chain reaction (PCR) can be used to amplify a DNAfragment with the concomitant creation of numerous mutations bymis-incorporation of nucleotides. This can be achieved by modifying thePCR conditions such as altering the ratios of dNTPs or adding variousamounts of manganese chloride in the reaction (Fromant et al., AnalBiochem, 224(1):347-53 (1995); Lin-Goerke et al., Biotechniques,23(3):409-12 (1997)). The pool of mutated DNA fragments can then becloned to yield a library of mutated plasmids that can then be screenedfollowing expression in a host such as E. coli.

The method of gene shuffling is particularly attractive due to itsfacile implementation, and high rate of mutagenesis and ease ofscreening. The process of gene shuffling involves the restrictionendonuclease cleavage of a gene of interest into fragments of specificsize in the presence of additional populations of DNA regions havingsimilarity and/or difference to the gene of interest. This pool offragments will then be denatured and reannealed to create a mutatedgene. The mutated gene is then screened for altered activity.

The instant sequences of the present invention may be mutated andscreened for altered or enhanced activity by this method. The sequencesshould be double-stranded and can be of various lengths ranging from 50by to 10 kB. The sequences may be randomly digested into fragmentsranging from about 10 by to 1000 bp, using restriction endonuclease wellknown in the art (Sambrook, J. and Russell, supra). In addition to theinstant microbial sequences, populations of fragments that arehybridizable to all or portions of the sequence may be added. Similarly,a population of fragments, which are not hybridizable to the instantsequence, may also be added. Typically these additional fragmentpopulations are added in about a 10 to 20 fold excess by weight ascompared to the total nucleic acid. Generally, if this process isfollowed, the number of different specific nucleic acid fragments in themixture will be about 100 to about 1000. The mixed population of randomnucleic acid fragments are denatured to form single-stranded nucleicacid fragments and then reannealed. Only those single-stranded nucleicacid fragments having regions of homology with other single-strandednucleic acid fragments will reanneal. The random nucleic acid fragmentsmay be denatured by heating. One skilled in the art could determine theconditions necessary to completely denature the double-stranded nucleicacid. Preferably the temperature is from about 80° C. to 100° C. Thenucleic acid fragments may be reannealed by cooling. Preferably thetemperature is from about 20° C. to 75° C. Renaturation may beaccelerated by the addition of polyethylene glycol (“PEG”) or salt. Asuitable salt concentration may range from 0 mM to 200 mM. The annealednucleic acid fragments are then incubated in the presence of a nucleicacid polymerase and dNTPs (i.e., dATP, dCTP, dGTP and dTTP). The nucleicacid polymerase may be the Klenow fragment, the Taq polymerase or anyother DNA polymerase known in the art. The polymerase may be added tothe random nucleic acid fragments prior to annealing, simultaneouslywith annealing or after annealing. The cycle of denaturation,renaturation and incubation in the presence of polymerase is repeatedfor a desired number of times. Preferably the cycle is repeated fromabout 2 to 50 times, more preferably the sequence is repeated from 10 to40 times. The resulting nucleic acid is a larger double-strandedpolynucleotide ranging from about 50 by to about 100 kB and may bescreened for expression and altered activity by standard cloning andexpression protocols (Sambrook, J. and Russell, supra).

Furthermore, a hybrid protein can be assembled by fusion of functionaldomains using gene shuffling (e.g., Nixon et al., PNAS, 94:1069-1073(1997)). The functional domain of the instant gene may be combined withthe functional domain of other genes to create novel enzymes withdesired catalytic function. A hybrid enzyme may be constructed using PCRoverlap extension methods and cloned into various expression vectorsusing the techniques well known to those skilled in art.

Suitable Reaction Conditions for the Enzyme-Catalyzed Preparation ofPeroxycarboxylic Acids from Carboxylic Acid Esters and Hydrogen Peroxide

In one aspect of the invention, a process is provided to produce anaqueous formulation comprising a peroxycarboxylic acid by reactingcarboxylic acid esters and a source of peroxygen including, but notlimited to, hydrogen peroxide, sodium perborate, and sodiumpercarbonate, in the presence of at least one of the present enzymecatalysts having perhydrolysis activity. In one embodiment, the presentenzyme catalyst comprises at least one of the present enzyme variantshaving perhydrolytic activity, wherein said enzyme is structurallyclassified as a member of the CE-7 carbohydrate esterase family. Inanother embodiment, the perhydrolase catalyst is a cephalosporin Cdeacetylase. In another embodiment, the perhydrolase catalyst is anacetyl xylan esterase.

In one embodiment, the perhydrolase catalyst comprises at least one ofthe present CE-7 variant polypeptides having perhydrolysis activitydisclosed herein.

Suitable carboxylic acid ester substrates may include esters provided bythe following formula:

[X]_(m)R₅

-   -   wherein X=an ester group of the formula R₆C(O)O    -   R₆=C1 to C7 linear, branched or cyclic hydrocarbyl moiety,        optionally substituted with hydroxyl groups or C1 to C4 alkoxy        groups, wherein R₆ optionally comprises one or more ether        linkages for R₆=C2 to C7;    -   R₅=a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety        optionally substituted with hydroxyl groups; wherein each carbon        atom in R₅ individually comprises no more than one hydroxyl        group or no more than one ester group; wherein R₅ optionally        comprises one or more ether linkages;    -   m=1 to the number of carbon atoms in R₅; and    -   wherein said esters have solubility in water of at least 5 ppm        at 25° C.

In other embodiments, suitable substrates may also include esters of theformula:

wherein R₁=C1 to C7 straight chain or branched chain alkyl optionallysubstituted with a hydroxyl or a C1 to C4 alkoxy group and R₂=C1 to C10straight chain or branched chain alkyl, alkenyl, alkynyl, aryl,alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂—O)_(n)H or(CH₂CH(CH₃)—O)_(n)H and n=1 to 10.

In other embodiments, suitable carboxylic acid ester substrates mayinclude glycerides of the formula:

wherein R₁ C1 to C7 straight chain or branched chain alkyl optionallysubstituted with a hydroxyl or a C1 to C4 alkoxy group and R₃ and R₄ areindividually H or R₁C(O).

In other embodiments, R₆ is C1 to C7 linear hydrocarbyl moiety,optionally substituted with hydroxyl groups or C1 to C4 alkoxy groups,optionally comprising one or more ether linkages. In further preferredembodiments, R₆ is C2 to C7 linear hydrocarbyl moiety, optionallysubstituted with hydroxyl groups, and/or optionally comprising one ormore ether linkages.

In other embodiments, suitable carboxylic acid ester substrates may alsoinclude acetylated saccharides selected from the group consisting ofacetylated mono-, di-, and polysaccharides. In additional embodiments,the acetylated saccharides include acetylated mono-, di-, andpolysaccharides. In further embodiments, the acetylated saccharides areselected from the group consisting of acetylated xylan; fragments ofacetylated xylan; acetylated xylose(such as xylose tetraacetate);acetylated glucose (such as glucose pentaacetate);β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal;tri-O-acetyl-D-glucal; and acetylated cellulose. In further embodiments,the acetylated saccharide is selected from the group consisting of13-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal;tri-O-acetyl-D-glucal; and acetylated cellulose. As such, acetylatedcarbohydrates may be suitable substrates for generating percarboxylicacids using the present methods and systems (La, in the presence of aperoxygen source).

In additional embodiments, the carboxylic acid ester substrate isselected from the group consisting of monoacetin; triacetin;monopropionin; dipropionin; tripropionin; monobutyrin; dibutyrin;tributyrin; glucose pentaacetate; xylose tetraacetate; acetylated xylan;acetylated xylan fragments; β-D-ribofuranose-1,2,3,5-tetraacetate;tri-O-acetyl-D-galactal; tri-O-acetyl-glucal; propylene glycoldiacetate; ethylene glycol diacetate; monoesters or diesters of1,2-ethanediol; 1,2-propanediol; 1,3-propanediol, 1,2-butanediol;1,3-butanediol; 2,3-butanediol; 1,4-butanediol; 1,2-pentanediol;2,5-pentanediol; 1,6-pentanediol; 1,2-hexanediol; 2,5-hexanediol;1,6-hexanediol; and mixtures thereof. In preferred embodiments of thepresent methods and systems, the substrate comprises triacetin.

The carboxylic acid ester is present in the reaction formulation at aconcentration sufficient to produce the desired concentration ofperoxycarboxylic acid upon enzyme-catalyzed perhydrolysis. Thecarboxylic acid ester need not be completely soluble in the reactionformulation, but has sufficient solubility to permit conversion of theester by the perhydrolase catalyst to the corresponding peroxycarboxylicacid. The carboxylic acid ester may be present in the reactionformulation at a concentration of 0.05 wt % to 40 wt % of the reactionformulation, preferably at a concentration of 0.1 wt % to 20 wt % of thereaction formulation, and more preferably at a concentration of 0.5 wt %to 10 wt % of the reaction formulation.

The peroxygen source may include, but is not limited to, hydrogenperoxide, hydrogen peroxide adducts (e.g., urea-hydrogen peroxide adduct(carbamide peroxide)) perborate salts and percarbonate salts. Theconcentration of peroxygen compound in the reaction formulation mayrange from 0.0033 wt % to about 50 wt %, preferably from 0.033 wt % toabout 40 wt %, more preferably from 0.33 wt % to about 30 wt %.

Many perhydrolase catalysts (whole cells, permeabilized whole cells, andpartially purified whole cell extracts) have been reported to havecatalase activity (EC 1.11.1.6). Catalases catalyze the conversion ofhydrogen peroxide into oxygen and water. In one aspect, theperhydrolysis catalyst lacks catalase activity. In another aspect, acatalase inhibitor is added to the reaction formulation. Examples ofcatalase inhibitors include, but are not limited to, sodium azide andhydroxylamine sulfate. One of skill in the art can adjust theconcentration of catalase inhibitor as needed. In one embodiment, theconcentration of the catalase inhibitor ranges from about 0.1 mM toabout 1 M; preferably about 1 about mM to about 50 mM; more preferablyfrom about 1 mM to about 20 mM. In one aspect, sodium azideconcentration typically ranges from about 20 mM to about 60 mM whilehydroxylamine sulfate is concentration is typically about 0.5 mM toabout 30 mM, preferably about 10 mM.

In another embodiment, the enzyme catalyst lacks significant catalaseactivity or is engineered to decrease or eliminate catalase activity.The catalase activity in a host cell can be down-regulated or eliminatedby disrupting expression of the gene(s) responsible for the catalaseactivity using well known techniques including, but not limited to,transposon mutagenesis, RNA antisense expression, targeted mutagenesis,and random mutagenesis.

In a preferred embodiment, the gene(s) encoding the endogenous catalaseactivity are down-regulated or disrupted (i.e., knocked-out). As usedherein, a “disrupted” gene is one where the activity and/or function ofthe protein encoded by the modified gene is no longer present. Means todisrupt a gene are well-known in the art and may include, but are notlimited to insertions, deletions, or mutations to the gene so long asthe activity and/or function of the corresponding protein is no longerpresent. In a further preferred embodiment, the production host is an E.coli production host comprising a disrupted catalase gene selected fromthe group consisting of katG and katE. In another embodiment, theproduction host is an E. coli strain comprising a down-regulation and/ordisruption in both katG and a katE catalase genes. An E. coli straincomprising a double-knockout of katG and katE is described herein as E.coli strain KLP18 (See Published U.S. Patent Application No.2008/0176299).

The concentration of the catalyst in the aqueous reaction formulationdepends on the specific catalytic activity of the catalyst, and ischosen to obtain the desired rate of reaction. The weight of catalyst inperhydrolysis reactions typically ranges from 0.0001 mg to 10 mg per mLof total reaction volume, preferably from 0.001 mg to 2.0 mg per mL. Thecatalyst may also be immobilized on a soluble or insoluble support usingmethods well-known to those skilled in the art; see for example,Immobilization of Enzymes and Cells; Gordon F. Bickerstaff, Editor;Humana Press, Totowa, N.J., USA; 1997. The use of immobilized catalystspermits the recovery and reuse of the catalyst in subsequent reactions.The enzyme catalyst may be in the form of whole microbial cells,permeabilized microbial cells, microbial cell extracts,partially-purified or purified enzymes, and mixtures thereof.

In one aspect, the concentration of peroxycarboxylic acid generated bythe combination of chemical perhydrolysis and enzymatic perhydrolysis ofthe carboxylic acid ester is sufficient to provide an effectiveconcentration of peroxycarboxylic acid for disinfection, bleaching,sanitization, deodoring or destaining at a desired pH. In anotheraspect, the present methods provide combinations of enzymes and enzymesubstrates to produce the desired effective concentration ofperoxycarboxylic acid, where, in the absence of added enzyme, there is asignificantly lower concentration of peroxycarboxylic acid produced.Although there may in some cases be substantial chemical perhydrolysisof the enzyme substrate by direct chemical reaction of inorganicperoxide with the enzyme substrate, there may not be a sufficientconcentration of peroxycarboxylic add generated to provide an effectiveconcentration of peroxycarboxylic acid in the desired applications, anda significant increase in total peroxycarboxylic acid concentration isachieved by the addition of an appropriate perhydrolase catalyst to thereaction formulation.

The concentration of peroxycarboxylic acid generated (such as peraceticacid) by the perhydrolysis of at least one carboxylic acid ester is atleast about 20 ppm, preferably at least 100 ppm, more preferably atleast about 200 ppm peroxycarboxylic acid, more preferably at least 300ppm, more preferably at least 500 ppm, more preferably at least 700 ppm,more preferably at least about 1000 ppm peroxycarboxylic acid, morepreferably at least 2000 ppm, even more preferably at least 3000 ppm,and most preferably at least 4000 ppm peroxycarboxylic acid within 10minutes, preferably within 5 minutes, and moost preferably within 1minute of initiating the perhydrolysis reaction (i.e., time measuredfrom combining the reaction components to form the reactionformulation). The product formulation comprising the peroxycarboxylicacid may be optionally diluted with water, or a solution predominantlycomprised of water, to produce a formulation with the desired lowerconcentration of peroxycarboxylic acid. In one aspect, the reaction timerequired to produce the desired concentration of peroxycarboxylic acidis not greater than about two hours, preferably not greater than about30 minutes, more preferably not greater than about 10 minutes, and mostpreferably in about 5 minutes or less. A hard surface or inanimateobject contaminated with a concentration of a biological contaminant(s)is contacted with the peroxycarboxylic acid formed in accordance withthe processes described herein. In one embodiment, the hard surface orinanimate object is contacted with the peroxycarboxylic acid formed inaccordance with the processes described within about 5 minutes to about168 hours of combining said reaction components, or within about 5minutes to about 48 hours, or within about 5 minutes to 2 hours ofcombining said reaction components, or any such time interval therein.

In another aspect, the peroxycarboxylic acid formed in accordance withthe processes describe herein is used in a laundry care applicationwherein the peroxycarboxylic acid is contacted with a textile to providea benefit, such as disinfecting, bleaching, destaining, deodorizingand/or a combination thereof. The peroxycarboxylic acid may be used in avariety of laundry care products including, but not limited to, textilepre-wash treatments, laundry detergents, stain removers, bleachingcompositions, deodorizing compositions, and rinsing agents. In oneembodiment, the present process to produce a peroxycarboxylic acid for atarget surface is conducted in situ.

In the context of laundry care applications, the term “contacting anarticle of clothing or textile” means that the article of clothing ortextile is exposed to a formulation disclosed herein. To this end, thereare a number of formats the formulation may be used to treat articles ofclothing or textiles including, but not limited to, liquid, solids, gel,paste, bars, tablets, spray, foam, powder, or granules and can bedelivered via hand dosing, unit dosing, dosing from a substrate,spraying and automatic dosing from a laundry washing or drying machine.Granular compositions can also be in compact form; liquid compositionscan also be in a concentrated form.

When the formulations disclosed herein are used in a laundry machine,the formulation can further contain components typical to laundrydetergents. For example, typical components included, but are notlimited to, surfactants, bleaching agents, bleach activators, additionalenzymes, suds suppressors, dispersants, lime-soap dispersants, soilsuspension and anti-redeposition agents, softening agents, corrosioninhibitors, tarnish inhibitors, germicides, pH adjusting agents,non-builder alkalinity sources, chelating agents, organic and/orinorganic fillers, solvents, hydrotropes, optical brighteners, dyes, andperfumes.

The formulations disclosed herein can also be used as detergent additiveproducts in solid or liquid form. Such additive products are intended tosupplement or boost the performance of conventional detergentcompositions and can be added at any stage of the cleaning process.

In connection with the present systems and methods for laundry carewhere the peracid is generated for one or more of bleaching, stainremoval, and odor reduction, the concentration of peracid generated(e.g., peracetic acid) by the perhydrolysis of at least one carboxylicacid ester may be at least about 2 ppm, preferably at least 20 ppm,preferably at least 100 ppm, and more preferably at least about 200 ppmperacid. In connection with the present systems and methods for laundrycare where the peracid is generated for disinfection or sanitization,the concentration of peracid generated (e.g., peracetic acid) by theperhydrolysis of at least one carboxylic acid ester may be at leastabout 2 ppm, more preferably at least 20 ppm, more preferably at least200 ppm, more preferably at least 500 ppm, more preferably at least 700ppm, more preferably at least about 1000 ppm peracid, most preferably atleast 2000 ppm peracid within 10 minutes, preferably within 5 minutes,and most preferably within 1 minute of initiating the perhydrolysisreaction. The product formulation comprising the peracid may beoptionally diluted with water, or a solution predominantly comprised ofwater, to produce a formulation with the desired lower concentration ofperacid. In one aspect of the present methods and systems, the reactiontime required to produce the desired concentration of peracid is notgreater than about two hours, preferably not greater than about 30minutes, more preferably not greater than about 10 minutes, even morepreferably not greater than about 5 minutes, and most preferably inabout 1 minute or less.

The temperature of the reaction is chosen to control both the reactionrate and the stability of the enzyme catalyst activity. The temperatureof the reaction may range from just above the freezing point of thereaction formulation (approximately 0° C.) to about 95° C., with apreferred range of reaction temperature of from about 5° C. to about 55°C.

The pH of the final reaction formulation containing peroxycarboxylicacid may range from about 2 to about 9, preferably from about 3 to about8, more preferably from about 5 to about 8, even more preferably about 6to about 8, and yet even more preferably about 6.5 to about 7.5. Inanother embodiment, the pH of the reaction formulation may be acidic(pH<7), The pH of the reaction, and of the final reaction formulation,may optionally be controlled by the addition of a suitable buffer,including, but not limited to phosphate, pyrophosphate,methylphosphonate, bicarbonate, acetate, or citrate, and combinationsthereof, The concentration of buffer, when employed, is typically from0.1 mM to 1.0 M, preferably from 1 mM to 300 mM, most preferably from 10mM to 100 mM.

In another aspect, the enzymatic perhydrolysis reaction formulation maycontain an organic solvent that acts as a dispersant to enhance the rateof dissolution of the carboxylic acid ester in the reaction formulation.Such solvents include, but are not limited to, propylene glycol methylether, acetone, cyclohexanone, diethylene glycol butyl ether,tripropylene glycol methyl ether, diethylene glycol methyl ether,propylene glycol butyl ether, dipropylene glycol methyl ether,cyclohexanol, benzyl alcohol, isopropanol, ethanol, propylene glycol,and mixtures thereof.

In another aspect, the enzymatic perhydrolysis product may containadditional components that provide desirable functionality. Theseadditional components include, but are not limited to, buffers,detergent builders, thickening agents, emulsifiers, surfactants, wettingagents, corrosion inhibitors (such as benzotriazole), enzymestabilizers, and peroxide stabilizers (e.g., metal ion chelatingagents). Many of the additional components are well known in thedetergent industry (see, for example, U.S. Pat. No. 5,932,532; herebyincorporated by reference). Examples of emulsifiers include, but are notlimited to, polyvinyl alcohol or polyvinylpyrrolidone. Examples ofthickening agents include, but are not limited to, LAPONITE®, cornstarch, PVP, CARBOWAX®, CARBOPOL®, CABOSIL®, polysorbate 20, PVA, andlecithin. Examples of buffering systems include, but are not limited tosodium phosphate monobasic/sodium phosphate dibasic; sulfamicacid/triethanolamine; citric acid/triethanolamine; tartaricacid/triethanolamine; succinic acid/triethanolamine; and aceticacid/triethanolamine. Examples of surfactants include, but are notlimited to a) non-ionic surfactants such as block copolymers of ethyleneoxide or propylene oxide, ethoxylated or propoxylated linear andbranched primary and secondary alcohols, and aliphatic phosphine oxides;b) cationic surfactants such as quaternary ammonium compounds,particularly quaternary ammonium compounds having a C8-C20 alkyl groupbound to a nitrogen atom additionally bound to three C1-C2 alkyl groups;c) anionic surfactants such as alkane carboxylic acids (e.g., C8-C20fatty acids), alkyl phosphonates, alkane sulfonates (e.g., sodiumdodecylsulphate “SDS”) or linear or branched alkyl benzene sulfonates,alkene sulfonates; and d) amphoteric and zwitterionic surfactants suchas aminocarboxylic acids, aminodicarboxylic acids, alkybetaines, andmixtures thereof. Additional components may include fragrances, dyes,stabilizers of hydrogen peroxide (e.g., metal chelators such as1-hydroxyethylidene-1,1-diphosphonic acid (DEQUEST® 2010, Solutia Inc.,St. Louis, Mo. and ethylenediaminetetraacetic acid (EDTA)), TURPINAL® SL(CAS# 2809-21-4), DEQUEST® 0520, DEQUEST® 0531, stabilizers of enzymeactivity (e.g., polyethylene glycol (PEG)), and detergent builders.

In Situ Production of Peroxycarboxylic Acids using a PerhydrolaseCatalyst

Cephalosporin C deacetylases (EC. 31.1.41; systematic name cephalosporinC acetylhydrolases; CAHs) are enzymes having the ability to hydrolyzethe acetyl ester bond on cephalosporins such as cephalosporin C,7-aminocephalosporanic acid, and7-(thiophene-2-acetamido)cephalosporanic acid (Abbott, B. and Fukuda,D., Appl. Microbiol. 30(3):413-419 (1975)). CAHs belong to a largerfamily of structurally related enzymes referred to as the carbohydrateesterase family seven (“CE-7”; see Coutinho, P. M., Henrissat, B.,supra). As used herein, the terms “CE-7”, “CE-7 esterase”, “CE-7carbohydrate esterase”, “CE-7 perhydrolase”, and “CE-7 enzyme” will beused interchangeably to refer to an enzyme structurally classified as amember of the carbohydrate esterase family 7.

Members of the CE-7 enzyme family may be found in plants, fungi (e.g.,Cephalosporidium acremonium), yeasts (e.g., Rhodosporidium toruloides,Rhodotorula glutinis), and bacteria such as Thermoanaerobacterium sp.;Norcardia lactamdurans, and various members of the genus Bacillus(Politino et al., Appl. Environ. Microbiol., 63(12):4807-4811 (1997);Sakai et al., J. Ferment, Bioeng. 85:53-57 (1998); Lorenz, W. andWiegel, J., J. Bacteriol 179:5436-5441 (1997); Cardoza et al., Appl.Microbiol. Biotechnol., 54(3):406-412 (2000); Mitsushima et al., (1995)Appl. Env. Microbiol. 61(6):2224-2229; Abbott, B. and Fukuda, D., Appl.Microbiol. 30(3):413-419 (1975); Vincent et al., supra, Takami et al.,NAR, 28(21):4317-4331 (2000); Rey et al., Genome Biol., 5(10): article77 (2004); Degrassi et al., Microbiology., 146:1585-1591 (2000); U.S.Pat. No. 6,645,233; U.S. Pat. No. 5,281,525; U.S. Pat. No. 5,338,676;and WO 99/03984. WO2007/070609 and U.S. Patent Application PublicationNos. 2008/0176299, 2008/176783, and 2009/0005590 to DiCosimo et al.disclose various enzymes structurally classified as CE-7 enzymes thathave perhydrolysis activity suitable for producing efficaciousconcentrations of peroxycarboxylic acids from a variety of carboxylicacid ester substrates when combined with a source of peroxygen.

The CE-7 family includes both CAHs and acetyl xylan esterases (AXEs;E.C. 3.1.1.72). CE-7 family members share a common structural motif andtypically exhibit ester hydrolysis activity for both acetylatedxylooligosaccharides and cephalosporin C, suggesting that the CE-7family represents a single class of proteins with a multifunctionaldeacetylase activity against a range of small substrates (Vincent et at,supra).

Vincent et al. analyzes the structural similarity among the members ofthis family and defines the signature motif characteristic of the CE-7family. The signature motif is a combination of at least 3 highlyconserved motifs as illustrated below. All sequence numbering isrelative to the numbering of a reference sequence (in this case, thewild type Thermotoga neapolitana perhydrolase; SEQ ID NO: 32).

As per the amino acid residue numbering of reference sequence SEQ ID NO:32, the CE-7 signature motif comprises 3 conserved motifs defined as:

a) Arg118-Gly119-Gln120;

b) Gly179-Xaa180-Ser181-Gln182-Gly183; and

c) His298-Glu299.

Typically, the Xaa at amino acid residue position 180 is glycine,alanine, proline, tryptophan, or threonine. Two of the three amino acidresidues belonging to the catalytic triad are in bold. In oneembodiment, the Xaa at amino acid residue position 180 is selected fromthe group consisting of glycine, alanine, proline, tryptophan, andthreonine.

Further analysis of the conserved motifs within the CE-7 carbohydrateesterase family indicates the presence of an additional conserved motif(LXD at amino acid positions 267-269 of SEQ ID NO: 32) that may be tofurther define a perhydrolase belonging to the CE-7 carbohydrateesterase family (FIGS. 1 and 2). In a further embodiment, the signaturemotif defined above includes a fourth conserved motif defined as:

Leu267-Xaa268-Asp269.

The Xaa at amino acid residue position 268 is typically isoleucine,valine, or methionine. The fourth motif includes the aspartic acidresidue (bold) that is the third member of the catalytic triad (Seri81-Asp269-His298).

Any number of well-known global alignment algorithms (i.e., sequenceanalysis software) may be used to align two or more amino acid sequences(representing enzymes having perhydrolase activity) to determine theexistence of the present signature motif (for example, CLUSTALW orNeedleman and Wunsch (J. Mol. Biol., 48:443-453 (1970)). The alignedsequence(s) is compared to the reference sequence (SEQ ID NO: 32). Inone embodiment, a CLUSTAL alignment (CLUSTALW) using a reference aminoacid sequence (as used herein the CAH sequence (SEQ ID NO: 32) from theThermotoga neapolitana) is used to identify perhydrolases belonging tothe CE-7 esterase family. The relative numbering of the conserved aminoacid residues is based on the residue numbering of the reference aminoacid sequence to account for small insertions or deletions (typically 5to 6 amino acids or less) within the aligned sequence as illustrated inTable A.

TABLE A Conserved motifs found within CE-7 enzymes having perhydrolaseactivity. Perhydrolase RGQ motif^(a) GXSQG motif^(a) LXD motif^(b) HEmotif^(a) Sequence (Residue #s) (Residue #s) (Residue #s) (Residue #s)SEQ ID NO: 32 118-120 186-190 272-274 303-304 SEQ ID NO: 36 118-120186-190 272-274 303-304 SEQ ID NO: 202 118-120 186-190 272-274 303-304SEQ ID NO: 203 118-120 186-190 272-274 303-304 SEQ ID NO. 204 118-120186-190 272-274 303-304 SEQ ID NO. 205 119-121 187-191 273-275 304-305^(a)= Conserved motifs defined by Vincent et al., supra, used to definethe signature motif. ^(b)= an additional motif that may be useful infurther defining the signature motif defined by Vincent et al., supra.

Each of the present CE-7 variants having perhydrolytic activity wasderived from one of the wild type perhydrolase sequences in Table A.Each of the present variants retain the CE-7 signature motif (i.e.,changes introduced to the wild type sequence do not include changes tothe conserved motifs provided in Table A.). More specifically, thepresent perhydrolases having improved activity have a substitution toamino acid residue 277 where the wild type cysteine is replaced withserine, threonine, valine or alanine (per the numbering of SEQ ID NOs:32, 36, 202, 203, and 204). The same substitution occurs at amino acidreside 278 in SEQ ID NO: 205 (i.e., SEQ ID NO: 205 contains a singleamino acid insertion that shifts the relative residue numbering by 1).

Each of the present variants comprises an improvement in perhydrolasespecific activity [U/mg protein], enzyme volumetric activity [U/mL] in areaction mixture, and/or an improvement in the ratio of perhydrolysisactivity to hydrolysis activity (i.e, the “P/H ratio”). In oneembodiment, the improvement in activity is measured as a fold increasein activity (perhydrolase specific activity [U/mg protein],perhydrolysis volumetric activity [U/mL] in a reaction mixture, and/orthe P/H ratio) relative to the wild type sequence from which it wasderived. In another embodiment, the fold improvement in enzyme activity(perhydrolysis specific activity, perhydrolysis volumetric activity,and/or an increase in the P/H ratio) for a variant CE-7 enzyme having atleast 95% amino acid sequence identity to SEQ ID NO: 5 is relative tothe activity measured for SEQ ID NO: 32; the fold improvement inactivity for a variant CE-7 enzyme having at least 95% amino acidsequence identity to SEQ ID NO: 10 is relative to the activity measuredfor SEQ ID NO: 36; the fold improvement in activity for a variant CE-7enzyme having at least 95% amino acid sequence identity to SEQ ID NO: 15is relative to the activity measured for SEQ ID NO: 202; the foldimprovement in activity for a variant CE-7 enzyme having at least 95%amino acid sequence identity to SEQ ID NO: 20 is relative to theactivity measured for SEQ ID NO: 203; the fold improvement in activityfor a variant CE-7 enzyme having at least 95% amino acid sequenceidentity to SEQ ID NO: 25 is relative to the activity measured for SEQID NO: 204; and the fold improvement in activity for a variant CE-7enzyme having at least 95% amino acid sequence identity to SEQ ID NO: 30is relative to the activity measured for SEQ ID NO: 205.

In one embodiment, the fold increase in perhydrolase specific activityfor the present variants is at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7,1.8, 1.9, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, or 13-foldwhen compared to the activity of the wild type sequence undersubstantially similar conditions.

In another embodiment, the fold increase in the P/H ratio for thepresent variants is at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,1.9, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0 or 10-fold when compared tothe P/H ratio of the wild type sequence under substantially similarconditions.

The present method produces industrially-useful, efficaciousconcentrations of peroxycarboxylic acids under aqueous reactionconditions using the perhydrolase activity of a variant enzyme belongingto the CE-7 family of carbohydrate esterases. In one embodiment, thepresent method produces efficacious concentrations of one or moreperoxycarboxylic acids in situ.

HPLC Assay Method for Determining the Concentration of Peracid andHydrogen Peroxide.

A variety of analytical methods can be used in the present method toanalyze the reactants and products including, but not limited totitration, high performance liquid chromatography (HPLC), gaschromatography (GC), mass spectroscopy (MS), capillary electrophoresis(CE), the analytical procedure described by U. Karst et al., (Anal.Chem., 69(17):3623-3627 (1997)), and the2,2′-azino-bis(3-ethylbenzothazoline)-6-sulfonate (ABTS) assay (S.Minning, et al., Analytica Chimica Acta 378:293-298 (1999) and WO2004/058961 A1) as described in the present examples.

Determination of Minimum Biocidal Concentration of Peracids

The method described by J. Gabrielson, et al. (J. Microbiol. Methods 50:63J3 (2002)) can be employed for determination of the Minimum BiocidalConcentration (MBC) of peracids, or of hydrogen peroxide and enzymesubstrates. The assay method is based on XTT reduction inhibition, whereXTT((2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium,inner salt, monosodium salt) is a redox dye that indicates microbialrespiratory activity by a change in optical density (OD) measured at 490nm or 450 nm. However, there are a variety of other methods availablefor testing the activity of disinfectants and antiseptics including, butnot limited to viable plate counts, direct microscopic counts, dryweight, turbidity measurements, absorbance, and bioluminescence (see,for example Brock, Semour S., Disinfection, Sterilization, andPreservation, 5^(th) edition, Lippincott Williams & Wilkins,Philadelphia, Pa., USA; 2001).

Uses of Enzymatically-Prepared Peroxycarboxylic Acid Compositions

The enzyme catalyst-generated peroxycarboxylic acid produced accordingto the present method can be used in a variety of hard surface/inanimateobject applications for reduction of concentrations of biologicalcontaminants, such as decontamination of medical instruments (e.g.,endoscopes), textiles (e.g., garments, carpets), food preparationsurfaces, food storage and food-packaging equipment, materials used forthe packaging of food products, chicken hatcheries and grow-outfacilities, animal enclosures, and spent process waters that havemicrobial and/or virucidal activity. The enzyme-generatedperoxycarboxylic acids may be used in formulations designed toinactivate prions (e.g., certain proteases) to additionally providebiocidal activity. In a preferred aspect, the present peroxycarboxylicacid compositions are particularly useful as a disinfecting agent fornon-autociavable medical instruments and food packaging equipment. Asthe peroxycarboxylic acid-containing formulation may be prepared usingGRAS or food-grade components (enzyme, enzyme substrate, hydrogenperoxide, and buffer), the enzyme-generated peracid may also be used fordecontamination of animal carcasses, meat, fruits and vegetables, or fordecontamination of prepared foods. The enzyme-generated peroxycarboxylicacid may be incorporated into a product whose final form is a powder,liquid, gel, film, solid or aerosol. The enzyme-generatedperoxycarboxylic acid may be diluted to a concentration that stillprovides an efficacious decontamination.

The compositions comprising an efficacious concentration ofperoxycarboxylic acid can be used to disinfect surfaces and/or objectscontaminated (or suspected of being contaminated) with biologicalcontaminants by contacting the surface or object with the productsproduced by the present processes. As used herein, “contacting” refersto placing a disinfecting composition comprising an effectiveconcentration of peroxycarboxylic acid in contact with the surface orinanimate object suspected of contamination with a disease-causingentity for a period of time sufficient to clean and disinfect.Contacting includes spraying, treating, immersing, flushing, pouring onor in, mixing, combining, painting, coating, applying, affixing to andotherwise communicating a peroxycarboxylic acid solution or compositioncomprising an efficacious concentration of peroxycarboxylic acid, or asolution or composition that forms an efficacious concentration ofperoxycarboxylic acid, with the surface or inanimate object suspected ofbeing contaminated with a concentration of a biological contaminant. Thedisinfectant compositions may be combined with a cleaning composition toprovide both cleaning and disinfection. Alternatively, a cleaning agent(e.g., a surfactant or detergent) may be incorporated into theformulation to provide both cleaning and disinfection in a singlecomposition.

The compositions comprising an efficacious concentration ofperoxycarboxylic acid can also contain at least one additionalantimicrobial agent, combinations of prion-degrading proteases, avirucide, a sporicide, or a biocide. Combinations of these agents withthe peroxycarboxylic acid produced by the claimed processes can providefor increased and/or synergistic effects when used to clean anddisinfect surfaces and/or objects contaminated (or suspected of beingcontaminated) with biological contaminants, such as microorganisms,spores, viruses, fungi, and/or prions. Suitable antimicrobial agentsinclude carboxylic esters (e.g., p-hydroxy alkyl benzoates and alkylcinnamates); sulfonic acids (e.g., dodecylbenzene sulfonic acid);iodo-compounds or active halogen compounds (e.g., elemental halogens,halogen oxides (e.g., NaOCl, HOCl, HOBr, ClO₂), iodine, interhalides(e.g., iodine monochloride, iodine dichloride, iodine trichloride,iodine tetrachloride, bromine chloride, iodine monobromide, or iodinedibromide); polyhalides; hypochlorite salts; hypochlorous acid;hypobromite salts; hypobromous acid; chloro- and bromo-hydantoins;chlorine dioxide; and sodium chlorite); organic peroxides includingbenzoyl peroxide, alkyl benzoyl peroxides, ozone, singlet oxygengenerators, and mixtures thereof, phenolic derivatives (e.g., o-phenylphenol, o-benzyl-p-chlorophenol, tert-amyl phenol and C₁-C₆ alkylhydroxy benzoates), quaternary ammonium compounds (such asalkyldimethylbenzyl ammonium chloride, dialkyldimethyl ammonium chlorideand mixtures thereof); and mixtures of such antimicrobial agents, in anamount sufficient to provide the desired degree of microbial protection.Effective amounts of antimicrobial agents include about 0.001 wt % toabout 60 wt % antimicrobial agent, about 0.01 wt % to about 15 wt %antimicrobial agent, or about 0.08 wt % to about 2.5 wt % antimicrobialagent.

In one aspect, the peroxycarboxylic acids formed by the present processcan be used to reduce the concentration of viable biologicalcontaminants (such as a viable microbial population) when applied onand/or at a locus. As used herein, a “locus” comprises part or all of atarget surface suitable for disinfecting or bleaching. Target surfacesinclude all surfaces that can potentially be contaminated withbiological contaminants. Non-limiting examples include equipmentsurfaces found in the food or beverage industry (such as tanks,conveyors, floors, drains, coolers, freezers, equipment surfaces, walls,valves, belts, pipes, drains, joints, crevasses, combinations thereof,and the like); building surfaces (such as walls, floors and windows);non-food-industry related pipes and drains, including water treatmentfacilities, pools and spas, and fermentation tanks; hospital orveterinary surfaces (such as walls, floors, beds, equipment (such asendoscopes), clothing worn in hospital/veterinary or other healthcaresettings, including clothing, scrubs, shoes, and other hospital orveterinary surfaces); restaurant surfaces; bathroom surfaces; toilets;clothes and shoes; surfaces of barns or stables for livestock, such aspoultry, cattle, dairy cows, goats, horses and pigs; hatcheries forpoultry or for shrimp; and pharmaceutical or biopharmaceutical surfaces(e.g., pharmaceutical or biopharmaceutical manufacturing equipment,pharmaceutical or biopharmaceutical ingredients, pharmaceutical orbiopharmaceutical excipients). Additional hard surfaces also includefood products, such as beef, poultry, pork, vegetables, fruits, seafood,combinations thereof, and the like. The locus can also include waterabsorbent materials such as infected linens or other textiles. The locusalso includes harvested plants or plant products including seeds, corms,tubers, fruit, and vegetables, growing plants, and especially cropgrowing plants, including cereals, leaf vegetables and salad crops, rootvegetables, legumes, berried fruits, citrus fruits and hard fruits.

Non-limiting examples of hard surface materials are metals (e.g., steel,stainless steel, chrome, titanium, iron, copper, brass, aluminum, andalloys thereof), minerals (e.g., concrete), polymers and plastics (e.g.,polyolefins, such as polyethylene, polypropylene, polystyrene,poly(meth)acrylate, polyacrylonitrile, polybutadiene,poly(acrylonitrile, butadiene, styrene), poly(acrylonitrile, butadiene),acrylonitrile butadiene; polyesters such as polyethylene terephthalate;and polyamides such as nylon). Additional surfaces include brick, tile,ceramic, porcelain, wood, vinyl, linoleum, and carpet.

The peroxycarboxylic acids formed by the present process may be used toprovide a benefit to an article of clothing or a textile including, butnot limited to, disinfecting, sanitizing, bleaching, destaining, anddeodorizing. The peroxycarboxylic acids formed by the present processmay be used in any number of laundry care products including, but notlimited to, textile pre-wash treatments, laundry detergents, stainremovers, bleaching compositions, deodorizing compositions, and rinsingagents.

Recombinant Microbial Expression

The genes and gene products of the instant sequences may be produced inheterologous host cells, particularly in the cells of microbial hosts.Preferred heterologous host cells for expression of the instant genesand nucleic acid molecules are microbial hosts that can be found withinthe fungal or bacterial families and which grow over a wide range oftemperature, pH values, and solvent tolerances. For example, it iscontemplated that any of bacteria, yeast, and filamentous fungi maysuitably host the expression of the present nucleic acid molecules. Theperhydrolase may be expressed intracellularly, extracellularly, or acombination of both intracellularly and extracellularly, whereextracellular expression renders recovery of the desired protein from afermentation product more facile than methods for recovery of proteinproduced by intracellular expression. Transcription, translation and theprotein biosynthetic apparatus remain invariant relative to the cellularfeedstock used to generate cellular biomass; functional genes will beexpressed regardless. Examples of host strains include, but are notlimited to bacterial, fungal or yeast species such as Aspergillus,Trichoderma, Saccharomyces, Pichia, Phaffia, Kluyveromyces, Candida,Hansenula, Yarrowia, Salmonella, Bacillus, Acinetobacter, Zymomonas,Agrobacterium, Erythrobacter, Chlorobium, Chromatium, Flavobacterium,Cytophaga, Rhodobacter, Rhodococcus, Streptomyces, Brevibacterium,Corynebacteria, Mycobacterium, Deinococcus, Escherichia, Erwinia,Pantoea, Pseudomonas, Sphingomonas, Methylomonas, Methylobacter,Methylococcus, Methylosinus, Methylomicrobium, Methylocystis,Alcaligenes, Synechocystis, Synechococcus, Anabaena, Thiobacillus,Methanobacterium, Klebsiella, and Myxococcus. In one embodiment,bacterial host strains include Escherichia, Bacillus, Kluyveromyces, andPseudomonas. In a preferred embodiment, the bacterial host cell isEscherichia coli.

Large-scale microbial growth and functional gene expression may use awide range of simple or complex carbohydrates, organic acids andalcohols or saturated hydrocarbons, such as methane or carbon dioxide inthe case of photosynthetic or chemoautotrophic hosts, the form andamount of nitrogen, phosphorous, sulfur, oxygen, carbon or any tracemicronutrient including small inorganic ions. The regulation of growthrate may be affected by the addition, or not, of specific regulatorymolecules to the culture and which are not typically considered nutrientor energy sources.

Vectors or cassettes useful for the transformation of suitable hostcells are well known in the art. Typically the vector or cassettecontains sequences directing transcription and translation of therelevant gene, a selectable marker, and sequences allowing autonomousreplication or chromosomal integration. Suitable vectors comprise aregion 5′ of the gene which harbors transcriptional initiation controlsand a region 3′ of the DNA fragment which controls transcriptionaltermination. It is most preferred when both control regions are derivedfrom genes homologous to the transformed host cell and/or native to theproduction host, although such control regions need not be so derived.

Initiation control regions or promoters, which are useful to driveexpression of the present cephalosporin C deacetylase coding region inthe desired host cell are numerous and familiar to those skilled in theart. Virtually any promoter capable of driving these genes is suitablefor the present invention including but not limited to, CYC1 HIS3, GAL1,GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRPS, URA3, LEU2, ENO, TPI (usefulfor expression in Saccharomyces); AOX1 (useful for expression inPichia); and lac, araB, tet, trp, IP_(L), IP_(R), T7, tac, and trc(useful for expression in Escherichia colt) as well as the amy, apr, nprpromoters and various phage promoters useful for expression in Bacillus.

Termination control regions may also be derived from various genesnative to the preferred host cell. In one embodiment, the inclusion of atermination control region is optional. In another embodiment, thechimeric gene includes a termination control region derived thepreferred host cell.

Industrial Production

A variety of culture methodologies may be applied to produce the presentperhydrolase catalyst. For example, large-scale production of a specificgene product overexpressed from a recombinant microbial host may beproduced by batch, fed-batch, and continuous culture methodologies.Batch and fed-batch culturing methods are common and well known in theart and examples may be found in Thomas D. Brock in Biotechnology: ATextbook of Industrial Microbiology, Second Edition, Sinauer Associates,Inc., Sunderland, Ma. (1989) and Deshpande, Mukund V., Appl. Biochem,Biotechnol., 36:227-234 (1992).

Commercial production of the desired perhydrolase catalyst may also beaccomplished with a continuous culture. Continuous cultures are an opensystem where a defined culture media is added continuously to abioreactor and an equal amount of conditioned media is removedsimultaneously for processing. Continuous cultures generally maintainthe cells at a constant high liquid phase density where cells areprimarily in log phase growth. Alternatively, continuous culture may bepracticed with immobilized cells where carbon and nutrients arecontinuously added, and valuable products, by-products or waste productsare continuously removed from the cell mass. Cell immobilization may beperformed using a wide range of solid supports composed of naturaland/or synthetic materials.

Recovery of the desired perhydrolase catalysts from a batchfermentation, fed-batch fermentation, or continuous culture, may beaccomplished by any of the methods that are known to those skilled inthe art. For example, when the enzyme catalyst is producedintracellularly, the cell paste is separated from the culture medium bycentrifugation or membrane filtration, optionally washed with water oran aqueous buffer at a desired pH, then a suspension of the cell pastein an aqueous buffer at a desired pH is homogenized to produce a cellextract containing the desired enzyme catalyst. The cell extract mayoptionally be filtered through an appropriate filter aid such as celiteor silica to remove cell debris prior to a heat-treatment step toprecipitate undesired protein from the enzyme catalyst solution. Thesolution containing the desired enzyme catalyst may then be separatedfrom the precipitated cell debris and protein by membrane filtration orcentrifugation, and the resulting partially-purified enzyme catalystsolution concentrated by additional membrane filtration, then optionallymixed with an appropriate excipient (for example, maltodextrin,trehalose, sucrose, lactose, sorbitol, mannitol, phosphate buffer,citrate buffer, or mixtures thereof) and spray-dried to produce a solidpowder comprising the desired enzyme catalyst.

When an amount, concentration, or other value or parameter is giveneither as a range, preferred range, or a list of upper preferable valuesand lower preferable values, this is to be understood as specificallydisclosing all ranges formed from any pair of any upper range limit orpreferred value and any lower range limit or preferred value, regardlessof whether ranges are separately disclosed. Where a range of numericalvalues is recited herein, unless otherwise stated, the range is intendedto include the endpoints thereof, and all integers and fractions withinthe range. It is not intended that the scope be limited to the specificvalues recited when defining a range.

General Methods

The following examples are provided to demonstrate preferredembodiments. It should be appreciated by those of skill in the art thatthe techniques disclosed in the examples which follow representtechniques discovered by the inventor to function well in the practiceof the methods disclosed herein, and thus can be considered toconstitute preferred modes for its practice. However, those of skill inthe art should, in light of the present disclosure, appreciate that manychanges can be made in the specific embodiments which are disclosed andstill obtain a like or similar result without departing from the spiritand scope of the presently disclosed methods.

All reagents and materials were obtained from DIFCO Laboratories(Detroit, Mich.), GIBCO/BRL (Gaithersburg, Md.), TCI America (Portland,Oreg.), Roche Diagnostics Corporation (Indianapolis, Ind.) orSigma-Aldrich Chemical Company (St. Louis, Mo.), unless otherwisespecified.

The following abbreviations in the specification correspond to units ofmeasure, techniques, properties, or compounds as follows: “sec” or “s”means second(s), “min” means minute(s), “h” or “hr” means hour(s), “4”means microliter(s), “mL” means milliliter(s), “L” means liter(s), “mM”means millimolar, “M” means molar, “mmol” means millimole(s), “ppm”means part(s) per million, “wt” means weight, “wt %” means weightpercent, “g” means gram(s), “μg” means microgram(s), “ng” meansnanogram(s), “g” means gravity, “HPLC” means high performance liquidchromatography, “dd H₂O” means distilled and deionized water, “dcw”means dry cell weight, “ATCC” or “ATCC®” means the American Type CultureCollection (Manassas, Va.), “U” means unit(s) of perhydrolase activity,“rpm” means revolution(s) per minute, and “EDTA” meansethylenediaminetetraacetic acid.

Example 1 Cloning and Expression of Acetyl Xylan Esterase fromThermotoga neapolitana

A coding region encoding an acetyl xylan esterase from Thermotoganeapolitana (GENBANK® accession # AAB70869, SEQ ID NO:32) wassynthesized using codons optimized for expression in E. coli (DNA 2.0,Menlo Park, Calif.). The coding region was subsequently amplified by PCR(0.5 min at 94° C., 0.5 min at 55° C., 1 min at 70° C., 30 cycles) usingprimers identified as SEQ ID NO:33 and SEQ ID NO:34. The resultingnucleic acid product (SEQ ID NO: 35) was subcloned into pTrcHis2-TOPO®(Invitrogen, Carlsbad, Calif.) to generate the plasmid identified aspSW196. The plasmid pSW196 was used to transform E. coli KLP18 togenerate the strain identified as KLP18/pSW196 (See Published U.S.Patent Application No. 200810176299 to DiCosimo et al., incorporatedherein by reference in its entirety). KLP18/pSW196 was gown in LB mediaat 37° C. with shaking up to OD_(600nm)=0.4-0.5, at which time IPTG wasadded to a final concentration of 1 mM, and incubation continued for 2-3h. Cells were harvested by centrifugation and SDS-PAGE was performed toconfirm expression of the perhydrolase at 20-40% of total solubleprotein.

Example 2 Fermentation of E. coli KLP18 Transformant Expressing T.neapolitana Acetyl Xylan Esterase

A fermentor seed culture was prepared by charging a 2-L shake flask with0.5 L seed medium containing yeast extract (Amberex 695, 5.0 g/L),K₂HPO₄ (10.0 g/L), KH₂PO₄(7,0 g/L), sodium citrate dihydrate (1.0 g/L),(NH₄)₂SO₄ (4.0 g/L), MgSO₄ heptahydrate (1.0 g/L) and ferric ammoniumcitrate (0.10 g/L). The pH of the medium was adjusted to 6.8, and themedium was sterilized in the flask. Post sterilization additionsincluded glucose (50 wt %, 10.0 mL) and 1 mL ampicillin (25 mg/mL) stocksolution. The seed medium was inoculated with a 1-mL culture of E. coliKLP18/pSW196 (Example 1) in 20% glycerol, and cultivated at 35° C. and300 rpm. The seed culture was transferred at ca. 1-20D₅₅₀ to a 14-Lfermentor (Braun Biotech, Allentown, Pa.) with 8 L of medium at 35° C.containing KH₂PO₄ (3.50 g/L), FeSO₄ heptahydrate (0.05 g/L), MgSO₄heptahydrate (2.0 g/L), sodium citrate dihydrate (1.90 g/L), yeastextract (Amberex 695, 5.0 g/L), Biospumex153K antifoam (0.25 mL/L,Cognis Corporation, Monheim, Germany), NaCl (1.0 g/L), CaCl₂ dihydrate(10 g/L), and NIT trace elements solution (10 mL/L). The trace elementssolution contained citric acid monohydrate (10 g/L), MnSO₄ hydrate (2g/L), NaCl (2 g/L), FeSO₄ heptahydrate (0.5 g/L), ZnSO₄ heptahydrate(0.2 g/L), CuSO₄ pentahydrate (0.02 g/L) and NaMoO₄ dihydrate (0.02g/L). Post sterilization additions included glucose solution (50% w/w,80.0 g) and ampicillin (25 mg/mL) stock solution (16.00 mL). Glucosesolution (50% w/w) was used for fed batch. Glucose feed was initiatedwhen glucose concentration decreased to 0.5 g/L, starting at 0.31 gfeed/min and increasing progressively each hour to 0.36, 0.42, 0.49,0.57, 0.66, 0.77, 0.90, 1.04, 1.21, 1,41, and 1.63 g/min respectively;the rate remained constant afterwards. Glucose concentration in themedium was monitored, and if the concentration exceeded 0.1 g/L the feedrate was decreased or stopped temporarily. Induction was initiatedbetween OD₅₅₀=56 and OD₅₅₀=80 with addition of 16 mL IPTG (0.5 M) forthe various strains. The dissolved oxygen (DO) concentration wascontrolled at 25% of air saturation. The DO was controlled first byimpeller agitation rate (400 to 1400 rpm) and later by aeration rate (2to 10 slpm). The pH was controlled at 6.8. NH₄OH (29% w/w) and H₂SO₄(20% w/v) were used for pH control. The head pressure was 0.5 bars. Thecells were harvested by centrifugation 16 h post IPTG addition.

Example 3 Modeling of Thermotoga neapolitana Acetyl Xylan Esterase

Amino acid sequences of acetyl xylan esterases from T. neapolitana (SEQID NO: 32) and Thermotoga maritima MSB8 (SEQ ID NO: 36) were alignedusing CLUSTALW (FIG. 1). The X-ray crystal structure of T. maritimaacetyl xylan esterase (1VLQ) was obtained from the ResearchCollaboratory for Structural Bioinformatics (RCSB) protein databank(PDP) (See H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N.Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne: The Protein Data Bank.Nucleic Acids Research, 28 pp. 235-242 (2000) and H. M. Berman, K.Henrick, H. Nakamura, Announcing the worldwide Protein Data Bank.,Nature Structural Biology 10 (12), p. 980 (2003). All T. maritime aminoacids that differ from the corresponding T. neapolitana amino acids werereplaced with the T. neapolitana amino acid using Accelrys DISCOVERYSTUDIO® 2.0 software (Protocols>Protein Modeling>Build mutants; AccelrysSoftware Inc., San Diego, Calif.). In addition, selenomethionines werereplaced with methionine. The number of models chosen for the output was3, the optimization level was set to “high” and Use DOPE method was setto “true”. Structure overlays and visualizations were done using PyMol™version 0.99 (DeLano Scientific LLC, Palo Alto, Calif.). Model qualitywas judged based on whether the catalytic triad (H303, S188, and D274)remained in the correct position and whether the overall structure wasretained with respect to the original model.

Example 4 Identification of Amino Acid Residues in Thermotoganeapolitana Acetyl Xylan Esterase for Saturation Mutagenesis

In addition to the canonical catalytic triad (H303, S188, and D274),several residues are also present within the acetyl xylan esteraseactive site based on the model. Substitution of one or more of theseresidues with an alternative amino acid might be expected to alter thefunctionality of the enzyme. However, the specific effects of suchsubstitutions are unknown a priori. Residues F213 (Phe213), 1276(Ile276), C277 (Cys277) and N93 (Asn93) of SEQ ID NO: 32 were selectedfor site-saturation mutagenesis. Residue Y92 (Tyr92) was not selectedbecause of the high level of conservation of this residue across theCE-7 family.

Example 5 Saturation Mutagenesis at Amino Acid Residue Positions F213,I276, C277 and N93 of Thermotoga neapolitana Acetyl Xylan Esterase

To individually change each of the four selected residues (F213,1276,C277, N93) to each of the other possible 19 amino acids, primers pairs(Table 1) were designed based on the codon optimized sequence of T.neapolitana acetyl xylan esterase (SEQ ID NO:35 in the plasmid pSW196(See Example 1 above and U.S. Patent Application Pub. No.2008/0176299)).

TABLE 1 Oligonucleotides used to change amino acid residues 277, 276,213 and 93 in T. neapolitana. forward 5′ to 3′ reverse 5′ to 3′ C277TNEA_C277Gf ggacactattGGCccgccgtcta TNEA_C277Gr TAGACGGCGGGCCAATAGTGTCC(SEQ ID NO: 42) (SEQ ID NO: 43) TNEA_C277Af ggacactattGCGccgccgtctaTNEA_C277Ar TAGACGGCGGCGCAATAGTGTCC (SEQ ID NO: 44) (SEQ ID NO: 45)TNEA_C277Vf ggacactattGTGccgccgtcta TNEA_C277Vr TAGACGGCGGCACAATAGTGTCC(SEQ ID NO: 46) (SEQ ID NO: 47) TNEA_C277Lf ggacactattCTGccgccgtctaTNEA_C277Lr TAGACGGCGGCAGAATAGTGTCC (SEQ ID NO: 48) (SEQ ID NO: 49)TNEA_C277If ggacactattATTccgccgtcta TNEA_C277Ir TAGACGGCGGAATAATAGTGTCC(SEQ ID NO: 50) (SEQ ID NO: 51) TNEA_C277Pf ggacactattCCGccgccgtctaTNEA_C277Pr TAGACGGCGGCGGAATAGTGTCC (SEQ ID NO: 52) (SEQ ID NO: 53)TNEA_C277Ff ggacactattTTTccgccgtcta TNEA_C277Fr TAGACGGCGGAAMATAGTGTCC(SEQ ID NO: 54) (SEQ ID NO: 55) TNEA_C277Yf ggacactattTATccgccgtctaTNEA_C277Yr TAGACGGCGGATAAATAGTGTCC (SEQ ID NO: 56) (SEQ ID NO: 57)TNEA_C277Wf ggacactattTGGccgccgtcta TNEA_C277Wr TAGACGGCGGCCAAATAGTGTCC(SEQ ID NO: 58) (SEQ ID NO: 59) TNEA_C277Sf ggacactattAGCccgccgtctaTNEA_C277Sr TAGACGGCGGGCTAATAGTGTCC (SEQ ID NO: 60) (SEQ ID NO: 61)TNEA_C277Tf ggacactattACCccgccgtcta TNEA_C277Tr TAGACGGCGGGGTAATAGTGTCC(SEQ ID NO: 62) (SEQ ID NO: 63) TNEA_C277Qf ggacactattCAGccgccgtctaTNEA_C277Qr TAGACGGCGGCTGAATAGTGTCC (SEQ ID NO: 64) (SEQ ID NO: 65)TNEA_C277Nf ggacactattAACccgccgtcta TNEA_C277Nr TAGACGGCGGGTTAATAGTGTCC(SEQ ID NO: 66) (SEQ ID NO: 67) TNEA_C277Df ggacactattGATccgccgtctaTNEA_C277Dr TAGACGGCGGATCAATAGTGTCC (SEQ ID NO: 68) (SEQ ID NO: 69)TNEA_C277Ef ggacactattGAAccgccgtcta TNEA_C277Er TAGACGGCGGTTCAATAGTGTCC(SEQ ID NO: 70) (SEQ ID NO: 71) TNEA_C277Rf ggacactattCGTccgccgtctaTNEA_C277Rr TAGACGGCGGACGAATAGTGTCC (SEQ ID NO: 72) (SEQ ID NO: 73)TNEA_C277Hf ggacactattCATccgccgtcta TNEA_C277Hr TAGACGGCGGATGAATAGTGTCC(SEQ ID NO: 74) (SEQ ID NO: 75) TNEA_C277Kf ggacactattAAAccgccgtctaTNEA_C277Kr TAGACGGCGGTTTAATAGTGTCC (SEQ ID NO: 76) (SEQ ID NO: 77)TNEA_C277Mf ggacactattATGccgccgtcta TNEA_C277Mr TAGACGGCGGCATAATAGTGTCC(SEQ ID NO: 78) (SEQ ID NO: 79) I276 TNEA_I276Gf gatggacactGGCtgtccgccgtTNEA_I276Gr ACGGCGGACAGCCAGTGTCCATC (SEQ ID NO: 80) (SEQ ID NO: 81)TNEA_I276Af gatggacactGCGtgtccgccgt TNEA_I276Ar ACGGCGGACACGCAGTGTCCATC(SEQ ID NO: 82) (SEQ ID NO: 83) TNEA_I276Vf gatggacactGTGtgtccgccgtTNEA_I276Vr ACGGCGGACACACAGTGTCCATC (SEQ ID NO: 84) (SEQ ID NO: 85)TNEA_I276Lf gatggacactCTGtgtccgccgt TNEA_I276Lr ACGGCGGACACAGAGTGTCCATC(SEQ ID NO: 86) (SEQ ID NO: 87) TNEA_I276Cf gatggacactTGCtgtccgccgtTNEA_I276Cr ACGGCGGACAGCAAGTGTCCATC (SEQ ID NO: 88) (SEQ ID NO: 89)TNEA_I276Pf gatggacactCCGtgtccgccgt TNEA_I276Pr ACGGCGGACACGGAGTGTCCATC(SEQ ID NO: 90) (SEQ ID NO: 91) TNEA_I276Ff gatggacactTTTtgtccgccgtTNEA_I276Fr ACGGCGGACAAAAAGTGTCCATC (SEQ ID NO: 92) (SEQ ID NO: 93)TNEA_I276Yf gatggacactTATtgtccgccgt TNEA_I276Yr ACGGCGGACAATAAGTGTCCATC(SEQ ID NO: 94) (SEQ ID NO: 95) TNEA_I276Wf gatggacactTGGtgtccgccgtTNEA_I276Wr ACGGCGGACACCAAGTGTCCATC (SEQ ID NO: 96) (SEQ ID NO: 97)TNEA_I276Sf gatggacactAGCtgtccgccgt TNEA_I276Sr ACGGCGGACAGCTAGTGTCCATC(SEQ ID NO: 98) (SEQ ID NO: 99) TNEA_I276Tf gatggacactACCtgtccgccgtTNEA_I276Tr ACGGCGGACAGGTAGTGTCCATC (SEQ ID NO: 100) (SEQ ID NO: 101)TNEA_I276Qf gatggacactCAGtgtccgccgt TNEA_I276Qr ACGGCGGACACTGAGTGTCCATC(SEQ ID NO: 102) (SEQ ID NO: 103) TNEA_I276Nf gatggacactAACtgtccgccgtTNEA_I276Nr ACGGCGGACAGTTAGTGTCCATC (SEQ ID NO: 104) (SEQ ID NO: 105)TNEA_I2760f gatggacactGATtgtccgccgt TNEA_I276Dr ACGGCGGACAATCAGTGTCCATC(SEQ ID NO: 106) (SEQ ID NO: 107) TNEA_I276Ef gatggacactGAAtgtccgccgtTNEA_I276Er ACGGCGGACATTCAGTGTCCATC (SEQ ID NO: 108) (SEQ ID NO: 109)TNEA_I276Rf gatggacactCGTtgtccgccgt TNEA_I276Rr ACGGCGGACAACGAGTGTCCATC(SEQ ID NO: 110) (SEQ ID NO: 111) TNEA_I276Hf gatggacactcATtgtccgccgtTNEA_I276Hr ACGGCGGACAATGAGTGTCCATC (SEQ ID NO: 112) (SEQ ID NO: 113)TNEA_I276Kf gatggacactAAAtgtccgccgt TNEA_I276Kr ACGGCGGAGATTTAGTGTCCATC(SEQ ID NO: 114) (SEQ ID NO: 115) TNEA_I276Mf gatggacactATGtgtccgccgtTNEA_I276Mr ACGGGGGACACATAGTGTCCATC (SEQ ID NO: 116) (SEQ ID NO: 117)F213 TNEA_F213Gf cgatgttccgGGCctgtgccact TNEA_F213GrAGTGGCACAGGCCCGGAACATCG (SEQ ID NO: 118) (SEQ ID NO: 119) TNEA_F213AfcgatgttccgGCGctgtgccact TNEA_F213Ar AGTGGCACAGCGCCGGAACATCG (SEQ ID NO:120) (SEQ ID NO: 121) TNEA_F213Vf cgatgttccgGTGctgtgccact TNEA_F213VrAGTGGCACAGCACCGGAACATCG (SEQ ID NO: 122) (SEQ ID NO: 123) TNEA_F213LfcgatgttccgCTGctgtgccact TNEA_F213Lr AGTGGCACAGCAGCGGAACATCG (SEQ ID NO:124) (SEQ ID NO: 125) TNEA_F213If cgatgttccgATTctgtgccact TNEA_F213IrAGTGGCACAGAATCGGAACATCG (SEQ ID NO: 126) (SEQ ID NO: 127) TNEA_F213PfcgatgttccgCCGctgtgccact TNEA_F213Pr AGTGGCACAGCGGCGGAACATCG (SEQ ID NO:128) (SEQ ID NO: 129) TNEA_F213Cf cgatgttccgTGCctgtgccact TNEA_F213CrAGTGGCACAGGCACGGAACATCG (SEQ ID NO: 130) (SEQ ID NO: 131) TNEA_F213YfcgatgttccgTATctgtgccact TNEA_F213Yr AGTGGCACAGATACGGAACATCG (SEQ ID NO:132) (SEQ ID NO: 133) TNEA_F213Wf cgatgttccgTGGctgtgccact TNEA_F213WrAGTGGCACAGCCACGGAACATCG (SEQ ID NO: 134) (SEQ ID NO: 135) TNEA_F213SfcgatgttccgAGCctgtgccact TNEA_F213Sr AGTGGCACAGGCTCGGAACATCG (SEQ ID NO:136) (SEQ ID NO: 137) TNEA_F213Tf cgatgttccgACCctgtgccact TNEA_F213TrAGTGGCACAGGGTCGGAACATCG (SEQ ID NO: 138) (SEQ ID NO: 139) TNEA_F213QfcgatgttccgCAGctgtgccact TNEA_F213Qr AGTGGCACAGCTGCGGAACATCG (SEQ ID NO:140) (SEQ ID NO: 141) TNEA_F213Nf cgatgttccgAACctgtgccact TNEA_F213NrAGTGGCACAGGTTCGGAAGATCG (SEQ ID NO: 142) (SEQ ID NO: 143) TNEA_F213DfcgatgttccgGATctgtgccact TNEA_F213Dr AGTGGCACAGATCCGGAACATCG (SEQ ID NO:144) (SEQ ID NO: 145) TNEA_F213Ef cgatgttccgGAActgtgccact TNEA_F213ErAGTGGCACAGTTCCGGAACATCG (SEQ ID NO: 146) (SEQ ID NO: 147) TNEA_F213RfcgatgttccgCGTctgtgccact TNEA_F213Rr AGTGGCACAGACGCGGAACATCG (SEQ ID NO:148) (SEQ ID NO: 149) TNEA_F213Hf cgatgttccgCATctgtgccact TNEA_F213HrAGTGGCACAGATGCGGAACATCG (SEQ ID NO: 150) (SEQ ID NO: 151) TNEA_F213KfcgatgttccgAAActgtgccact TNEA_F213Kr AGTGGCACAGTTTCGGAACATCG (SEQ ID NO:152) (SEQ ID NO: 153) TNEA_F213SMf cgatgttccgATGctgtgccact TNEA_F213MrAGTGGCACAGCATCGGAACATCG (SEQ ID NO: 154) (SEQ ID NO: 155) N093TNEA_N093Gf cattggttacGGCggtggccgtg TNEA_N093Gr CACGGCCACCGGCGTAACCAATG(SEQ ID NO: 156) (SEQ ID NO: 157) TNEA_N093Af cattggttacGCGggtggccgtgTNEA_N093Ar CACGGCCACCGCGGTAACCAATG (SEQ ID NO: 158) (SEQ ID NO: 159)TNEA_N093Vf cattggttacGTGggtggccgtg TNEA_N093Vr CACGGCCACCGTGGTAACCAATG(SEQ ID NO: 160) (SEQ ID NO: 161) TNEA_N093Lf cattggttacCTGggtggccgtgTNEA_N093Lr CACGGCCACCCTGGTAACCAATG (SEQ ID NO: 162) (SEQ ID NO: 163)TNEA_N093If cattggttacATTggtggccgtg TNEA_N093Ir CACGGCCACCATTGTAACCAATG(SEQ ID NO: 164) (SEQ ID NO: 165) TNEA_N093Pf cattggttacCCGggtggccgtgTNEA_N093Pr CACGGCCACCCCGGTAACCAATG (SEQ ID NO: 166) (SEQ ID NO: 167)TNEA_N093Cf cattggttacTGCggtggccgtg TNEA_N093Cr CACGGCCACCTGCGTAACCAATG(SEQ ID NO: 168) (SEQ ID NO: 169) TNEA_N093Yf cattggttacTATggtggccgtgTNEA_N093Yr CACGGCCACCTATGTAACCAATG (SEQ ID NO: 170) (SEQ ID NO: 171)TNEA_N093Wf cattggttacTGGggtggccgtg TNEA_N093Wr CACGGCCACCTGGGTAACCAATG(SEQ ID NO: 172) (SEQ ID NO: 173) TNEA_N093Sf cattggttacAGCggtggccgtgTNEA_N093Sr CACGGCCACCAGCGTAACCAATG (SEQ ID NO: 174) (SEQ ID NO: 175)TNEA_N093Tf cattggttacACCggtggccgtg TNEA_N093Tr CACGGCCACCACCGTAACCAATG(SEQ ID NO: 176) (SEQ ID NO: 177) TNEA_N093Qf cattggttacCAGggtggccgtgTNEA_N093Qr CACGGCCACCCAGGTAACCAATG (SEQ ID NO: 178) (SEQ ID NO: 179)TNEA_N093Ff cattggttacTTTggtggccgtg TNEA_N093Fr CACGGCCACCTTTGTAACCAATG(SEQ ID NO: 180) (SEQ ID NO: 181) TNEA_N093Df cattggttacGATggtggccgtgTNEA_N093Dr CACGGCCACCGATGTAACCAATG (SEQ ID NO: 182) (SEQ ID NO: 183)TNEA_N093Ef cattggttacGAAggtggccgtg TNEA_N093Er CACGGCCACCGAAGTAACCAATG(SEQ ID NO: 184) (SEQ ID NO: 185) TNEA_N093Rf cattggttacCGTggtggccgtgTNEA_N093Rr CACGGCCACCCGTGTAACCAATG (SEQ ID NO: 186) (SEQ ID NO: 187)TNEA_N093Hf cattggttacCATggtggccgtg TNEA_N093Hr CACGGCCACCCATGTAACCAATG(SEQ ID NO: 188) (SEQ ID NO: 189) TNEA_N093Kf cattggttacAAAggtggccgtgTNEA_N093Kr CACGGCCACCAAAGTAACCAATG (SEQ ID NO: 190) (SEQ ID NO: 191)TNEA_N093Mf cattggttacATGggtggccgtg TNEA_N093Mr CACGGCCACCATGGTAACCAATG(SEQ ID NO: 192) (SEQ ID NO: 193)

The mutations were made using QUIKCHANGE® (Stratagene, La Jolla, Calif.)kit according to the manufacturer's instructions. Amplified plasmidswere treated with 1U of Dpnl at 37° C. for 1 hour. Treated plasmids wereused to transform chemically competent E. coli XL1-Blue (Stratagene)(residues 213, 276 and 277) or chemically competent E. coli TOP10F′(Invitrogen, Carlsbad, Calif.) (residue 93). Transformants were platedon LB-agar supplemented with 0.1 mg ampicillin/mL and grown overnight at37° C. Up to five individual colonies were picked and the plasmid DNAsequenced to confirm the expected mutations.

Example 6 Perhydrolase Activity Assay of Thermotoga neapolitana AcetylXylan Esterase Mutants

Individual colonies of mutants were picked into 96-well platescontaining 0.1 mL LB with 0.1 mg ampicillin/mL, and grown overnight at37° C. without shaking. The overnight culture (0.003 mL) was transferredto an “Induction plate” (96 deep-well) containing 0.3 mL LB, 0.5 mM IPTGand 0.1 mg ampicillin/mL. Induction plates were grown overnight at 37°C. with shaking. 0.01 mL of Induction culture was transferred to “Lysisplate” (96-well) containing 0.09 mL of 56 mg/mL CELYTIC™ Express(Sigma-Aldrich, St. Louis, Mo.). Plates were slightly agitated first,before incubating at 25° C. for 30 minutes. Approximately 0.01 mL ofLysis culture was transferred to “Assay plate” (96-well) containing 0.09mL “Assay solution pH 5.0” (100 mM triacetin, 100 mM hydrogen peroxide,50 mM acetic acid pH 5.0). Approximately 0.01 mL of Lysis culture wasalso transferred to “Assay plate pH 7.5” (96-well) containing 0.09 mL“Assay solution pH 7.5” (100 mM triacetin, 100 mM hydrogen peroxide, 50mM sodium phosphate pH 7.5). Plates were gently agitated for 30 secondsbefore incubating at ambient temperature for 10 minutes. The assay wasquenched by addition of 0.1 mL of “Stop buffer” (100 mMortho-phenylenediamine (OPD), 500 mM NaH₂PO₄ pH 2.0). Plates were gentlyagitated for 30 seconds before incubating at 25° C. for 30 minutes. Theabsorbance was read at 458 nm without a lid using a SPECTRAMAX® Plus³⁸⁴(Molecular Devices, Sunnyvale, Calif.). Analysis of the resultsindicated four mutants that demonstrated significantly greaterperhydrolase activity compared to the native enzyme (Tables 2 and 3).All four are changes of the cysteine at residue 277 (C277A, C277V,C277S, and C277T; see SEQ ID NO: 5) increased perhydrolase activity.

TABLE 2 Perhydrolase activity (U/mL) at pH 5.0 of T. neapolitana acetylxylan esterase mutants. Mutant U/mL Mutant U/mL Mutant U/mL Mutant U/mLF213S 0.17 I276W 0.18 C277N 0.17 N093R 0.11 F213N 0.18 I276R 0.18 C277I0.17 N093I 0.10 F213G 0.17 I276L 0.18 C277S 0.43 N093Q 0.10 F213C 0.21I276K 0.18 C277A 0.51 N093K 0.11 F213V 0.17 I276M 0.18 C277Q 0.17 N093M0.10 F213M 0.17 I276V 0.26 C277L 0.17 N093C 0.12 F213T 0.17 I276S 0.17C277K 0.17 N093D 0.10 F213Y 0.23 I276N 0.18 C277V 0.35 N093S 0.12 F213I0.18 I276C 0.29 C277E 0.17 N093G 0.11 F213Q 0.17 I276Q 0.17 C277P 0.17N093V 0.10 F213H 0.22 I276F 0.27 C277D 0.17 N093L 0.13 F213R 0.20 I276H0.18 C277M 0.17 N09E 0.10 F213W 0.17 I276D 0.17 C277F 0.17 N093F 0.10F213P 0.17 I276E 0.18 C277T 0.33 N09A 0.11 F213D 0.17 I276G 0.17 C277Y0.17 N093H 0.11 F213K 0.17 I276Y 0.23 C277H 0.17 N093W 0.10 F213L 0.18I276T 0.29 C277W N/A N093P 0.10 F213E N/A I276A N/A C277R N/A N093Y 0.10F213A N/A I276P N/A C277G N/A N093T N/A native 0.16

TABLE 3 Perhydrolase activity at pH 7.5 of T. neapolitana acetyl xylanesterase mutants. Mutant U/mL Mutant U/mL Mutant U/mL Mutant U/mL F213S1.80 I276W 2.00 C277N 3.50 N093R 0.13 F213N 1.90 I276R 1.90 C277I 3.60N093I 0.10 F213G 1.70 I276L 2.00 C277S 9.30 N093Q 0.11 F213C 3.00 I276K1.90 C277A 7.50 N093K 0.13 F213V 1.70 I276M 1.90 C277Q 3.50 N093M 0.12F213M 1.90 I276V 3.40 C277L 3.60 N093C 0.15 F213T 1.80 I276S 1.90 C277K3.50 N093D 0.10 F213Y 2.60 I276N 2.10 C277V 6.10 N093S 0.23 F213I 1.80I276C 3.40 C277E 3.50 N093G 0.18 F213Q 1.80 I276Q 2.00 C277P 3.60 N093V0.10 F213H 2.30 I276F 2.70 C277D 3.70 N093L 0.22 F213R 2.20 I276H 2.10C277M 3.60 N09E 0.12 F213W 1.80 I276D 1.90 C277F 3.60 N093F 0.10 F213P3.50 I276E 1.90 C277T 9.60 N09A 0.13 F213D 3.60 I276G 3.60 C277Y 3.60N093H 0.18 F213K 3.60 I276Y 4.40 C277H 3.60 N093W 0.16 F213L 5.00 I276T3.00 C277W N/A N093P 0.12 F213E N/A I276A N/A C277R N/A N093Y 0.15 F213AN/A I276P N/A C277G N/A N093T N/A native 0.23

Example 7 Expression of Thermotoga neapolitana Acetyl Xylan EsteraseVariants in E. coli KLP18

Plasmids with confirmed acetyl xylan esterase mutations were used totransform E. coli KLP18 (Example 1). Transformants were plated ontoLB-ampicillin (100 pg/mL) plates and incubated overnight at 37° C. Cellswere harvested from a plate using 2.5 mL LB media supplemented with 20%(v/v) glycerol, and 1.0 mL aliquots of the resulting cell suspensionfrozen at −80° C. One mL of the thawed cell suspension was transferredto a 1-L APPLIKON® Bioreactor (Applikon® Biotechnology, Foster City,Calif.) with 0.7 L medium containing KH₂PO₄ (5.0 g/L), FeSO₄heptahydrate (0.05 g/L), MgSO₄ heptahydrate (1.0 g/L), sodium citratedihydrate (1.90 g/L), yeast extract (Amberex 695, 5.0 g/L),Biospumex153K antifoam (0.25 mL/L, Cognis Corporation), NaCl (1.0 g/L),CaCl₂ dihydrate (0.1 g/L), and NIT trace elements solution (10 mL/L).The trace elements solution contained citric acid monohydrate (10 g/L),MnSO₄ hydrate (2 g/L), NaCl (2 g/L), FeSO₄ heptahydrate (0.5 g/L), ZnSO₄heptahydrate (0.2 g/L), CuSO₄ pentahydrate (0.02 g/L) and NaMoO₄dihydrate (0.02 g/L). Post sterilization additions included glucosesolution (50% w/w, 6.5 g) and ampicillin (25 mg/mL) stock solution (2.8mL). Glucose solution (50% w/w) was also used for fed batch. Glucosefeed was initiated 40 min after glucose concentration decreased below0.5 g/L, starting at 0.03 g feed/min and increasing progressively eachhour to 0.04, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.12, and 0.14 g/minrespectively; the rate remaining constant afterwards. Glucoseconcentration in the medium was monitored, and if the concentrationexceeded 0.1 g/L the feed rate was decreased or stopped temporarily.Induction was initiated at OD₅₅₀=50 with addition of 0.8 mL IPTG (0.05M). The dissolved oxygen (DO) concentration was controlled at 25% of airsaturation, first by agitation (400-1000 rpm), and following by aeration(0.5-2 slpm). The temperature was controlled at 37° C., and the pH wascontrolled at 6.8; NH₄OH (29% w/w) and H₂SO₄ (20% w/v) were used for pHcontrol. The cells were harvested by centrifugation (5,000×g for 15minutes) at 20 h post IPTG addition.

Example 8 Preparation of Cell Lysates Containing Semi-Purified T.neapolitana Acetyl Xylan Esterase or T. neapolitana Variant Acetyl XylanEsterases

A cell culture of E. coli KLP18/pSW196 (Thermotoga neapolitana wild-typeperhydrolase) was grown as described in Example 2. The resulting cellpaste was resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0supplemented with 1.0 mM DTT. Resuspended cells were passed through aFrench pressure cell twice to ensure >95% cell lysis. Lysed cells werecentrifuged for 30 minutes at 12,000×g, and the supernatant was heatedat 75° C. for 20 minutes, followed by quenching in an ice bath for 2minutes. Precipitated protein was removed by centrifugation for 10minutes at 11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the heat-treated extractsupernatant.

Cell cultures of E. coli KLP18/pSW196/C277S (Thermotoga neapolitanaC277S variant perhydrolase), E. coli KLP18/pSW196/C277V (Thermotoganeapolitana C277V variant perhydrolase), E. coli KLP18/pSW196/C277A(Thermotoga neapolitana C277A variant perhydrolase), and E. coliKLP18/pSW196/C277T (Thermotoga neapolitana C277T variant perhydrolase)were each grown as described in Example 7. The resulting cell pasteswere resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0 supplementedwith 1.0 mM DTT. Resuspended cells were passed through a French pressurecell twice to ensure >95% cell lysis. Lysed cells were centrifuged for30 minutes at 12,000×g, and the supernatant was heated at 75° C. for 20minutes, followed by quenching in an ice bath for 2 minutes.Precipitated protein was removed by centrifugation for 10 minutes at11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the heat-treated extractsupernatant.

Example 9 Specific Activity and Perhydrolysis/Hydrolysis ratio of T.neapolitana Acetyl Xylan Wild-type Esterase and C277 Esterase Variantss

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and one of the following acetyl xylan esterase mutants: T.neapolitana C2775 variant perhydrolase (0.010 mg/mL of heat-treatedextract total protein from E. coli KLP18/pSW196/C277S), T. neapolitanaC277T variant perhydrolase (0.010 mg/mL of heat-treated extract totalprotein from E. coli KLP18/pSW196/C277T), T. neapolitana C277Avariantperhydrolase (0.0125 mg/mL of heat-treated extract total proteinfrom E. coli KLP18/pSW196/C277A), and T. neapolitana C277Vvariantperhydrolase (0.0125 mg/mL of heat-treated extract total proteinfrom E. coli KLP18/pSW196/C277V) (prepared as described in Example 8).Reactions were stirred for only the first 30 seconds of reaction toinitially mix the reactants and enzyme.

A reaction was also run under identical conditions to that describedimmediately above using 0.050 mg/mL of heat-treated extract totalprotein isolated from E. coli KLP18/pSW196 (expressing Thermotoganeapolitana wild-type acetyl xylan esterase (Example 1)), where theheat-treated extract supernatant was prepared according to the procedureof Example 8.

Two samples from each of the reaction mixtures described above weresimultaneously withdrawn after the first minute of each reaction, andevery two minutes thereafter for fifteen minutes, where one of the twosamples was analyzed for peracetic acid, and the second sample wasanalyzed for total acetic acid produced from both enzymatic hydrolysisof triacetin and from subsequent conversion of peracetic add in sampleto acetic acid by reaction with methyl-p-tolyl sulfide (MTS, see below).

Measurement of the rate of peracetic acid production in the reactionmixture was performed using a modification of the method described byKarst et al., supra. A sample (0.040 mL) of the reaction mixture wasremoved at a predetermined time and immediately mixed with 0.960 mL of 5mM phosphoric acid in water to terminate the reaction by adjusting thepH of the diluted sample to less than pH 4. The resulting solution wasfiltered using an ULTRAFREE® MC-filter unit (30,000 Normal MolecularWeight Limit (NMWL), Millipore Corp., Billerica, Mass.; cat #UFC3LKT 00)by centrifugation for 2 min at 12,000 rpm. An aliquot (0.100 mL) of theresulting filtrate was transferred to a 1.5-mL screw cap HPLC vial(Agilent Technologies, Palo Alto, Calif.; #5182-0715) containing 0.300mL of deionized water, then 0.100 mL of 20 mM MTS (methyl-p-tolylsulfide) in acetonitrile was added, the vial capped, and the contentsbriefly mixed prior to a 10 min incubation at ca. 25° C. in the absenceof light. To the vial was then added 0.400 mL of acetonitrile and 0.100mL of a solution of triphenylphosphine (TPP, 40 mM) in acetonitrile, thevial re-capped, and the resulting solution mixed and incubated at ca.25° C. for 30 min in the absence of light. To the vial was then added0.100 mL of 10 mM N,N-diethyl-m-toluamide (DEET; HPLC external standard)and the resulting solution analyzed by HPLC for MTSO (methyl-p-tolylsulfoxide), the stoichiometric oxidation product produced by reaction ofMTS with peracetic acid. A control reaction was run in the absence ofadded extract protein or triacetin to determine the rate of oxidation ofMTS in the assay mixture by hydrogen peroxide, for correction of therate of peracetic acid production for background MTS oxidation. HPLCmethod: Supelco Discovery C8 column (10-cm×4.0-mm, 5 μm) (catalog#569422-U) with Supelco Supelguard Discovery C8 precolumn(Sigma-Aldrich; catalog #59590-U); 10 microliter injection volume;gradient method with CH₃CN (Sigma-Aldrich; catalog #270717) anddeionized water at 1.0 mL/min and ambient temperature (Table 4).

TABLE 4 HPLC Gradient for analysis of peracetic acid. Time (min:sec) (%CH₃CN) 0:00 40 3:00 40 3:10 100 4:00 100 4:10 40 7:00 (stop) 40

For determination of the rate of perhydrolase-catalyzed acetic acidproduction in the reaction, a sample (0.900 mL) of the reaction mixturewas removed at a predetermined time and immediately added to a 1.5mL-microcentrifuge tube containing 0.040 mL of 0.75 M H₃PO₄, and theresulting solution briefly mixed to terminate the reaction at pH3.0-4.0. To the tube was then added 0.020 mL of a solution of 10 mg/mLof Aspergillus niger catalase (Sigma-Aldrich; C3515) in 50 mM phosphatebuffer pH (7.2), and the resulting solution mixed and allowed to reactfor 15 minutes at ambient temperature to disproportionate unreactedhydrogen peroxide to water and oxygen. To the tube was then added 0.040mL of 0.75 M H₃PO₄ and the resulting solution mixed and filtered usingan ULTRAFREE® MC-filter unit (30,000 Normal Molecular Weight Limit(NMWL), Millipore Corp., cat #UFC3LKT 00) by centrifugation for 2 min at12,000 rpm. An aliquot (0.100 mL) of the resulting filtrate was mixedwith 0.150 mL of 20 mM MTS (methyl-p-tolyl sulfide) in acetonitrile, andthe resulting solution was incubated for 10 min at ca. 25° C. in theabsence of light. The concentration of acetic acid in the sampleproduced by both enzymatic hydrolysis of triacetin and conversion ofperacetic acid to acetic acid by reaction with MTS was determined usinga gas chromatograph (GC) equipped with a flame ionization detector (FID)and a DB-FFAP column (length, 15 m; ID, 0.530 mm; film thickness, 1.00μm); a fresh injection port liner was employed for each ratedetermination (total of eight sample analyses) to avoid build up ofphosphoric acid in the injection port liner over time.

The Thermotoga neapolitana acetyl xylan esterase variants had asignificantly-higher specific activity for perhydrolysis of triacetinthan the wild-type esterase (Table 5). The perhydrolysis/hydrolysisratios for the T. neapolitana acetyl xylan esterase variants weredetermined by dividing the rate of PAA production (perhydrolysis rate)by the rate of hydrolysis of triacetin to acetic acid (hydrolysis rate)(calculated from the rate of total acetic acid production in the assaymethod from both PAA and acetic acid, and corrected for the rate ofperacetic acid production); the P/H ratio of the T. neapolitana acetylxylan esterase variants were ca. equal to or greater than the P/H ratiofor the T. neapolitana wild-type acetyl xylan esterase (Table 5).

TABLE 5 specific Thermotoga enzyme perhydrolysis hydrolysis activityneapolitana concen. rate rate P/H (U/mg perhydrolase (μg/mL) (mM/min)(mM/min) ratio protein) wild type 50 3.61 1.22 3.0 72 C277S 10 4.40 1.612.7 440 C277T 10 4.24 0.81 5.2 424 C277A 12.5 4.14 1.43 2.9 331 C277V12.5 3.70 0.88 4.2 296

Example 10 Cloning and Expression of Acetyl Xylan Esterase fromThermotoga maritima

A gene encoding acetyl xylan esterase from T. maritima as reported inGENBANK® (accession # NP_(—)227893.1) was synthesized (DNA 2.0, MenloPark Calif.). The gene was subsequently amplified by PCR (0.5 min at 94°C., 0.5 min at 55° C., 1 min at 70° C., 30 cycles) using primersidentified as SEQ ID NO: 206 and SEQ ID NO: 207. The resulting nucleicacid product (SEQ ID NO: 208) was cut with restriction enzymes PstI andXbaI and subcloned between the PstI and XbaI sites in pUC19 to generatethe plasmid identified as pSW207. A gene encoding an acetyl xylanesterase from T. maritima MSB8 as reported in GENBANK® (Accession no.NP_(—)227893.1; SEQ ID NO: 36) was synthesized using codons optimizedfor expression in E. coli (DNA 2.0, Menlo Park Calif.). The gene wassubsequently amplified by PCR (0.5 min at 94° C., 0.5 min at 55° C., 1min at 70° C., 30 cycles) using primers identified as SEQ ID NO:38 andSEQ ID NO:39. The resulting nucleic acid product (SEQ ID NO: 37) was cutwith restriction enzymes EcoRI and PstI and subcloned between the EcoRIand PstI sites in pTrc99A (GENBANK® Accession no. M22744) to generatethe plasmid identified as pSW228 (containing the codon-optimized T.maritima coding sequence SEQ ID NO: 41). The plasmids pSW207 and pSW228were used to transform E. coli KLP18 (U.S. Patent Application Pub. No.2008/0176299) to generate the strain identified as KLP18/pSW207 andKLP18/pSW228, respectively. KLP18/pSW207 and KLP18/pSW228 were gown inLB media at 37° C. with shaking up to OD_(600nm)=0.4-0.5, at which timeIPTG was added to a final concentration of 1 mM, and incubationcontinued for 2-3 h. Cells were harvested by centrifugation and SDS-PAGEwas performed to confirm expression of the perhydrolase at 20-40% oftotal soluble protein.

Example 11 Construction of Thermotoga maritima Acetyl Xylan EsteraseVariants at Residue C277

The C277 (Cys277) position of T. maritima acetyl xylan esterase waschanged to each of Val, Ala, Ser and Thr using oligonucleotide primerpairs (Table 6) that were designed based on the codon optimized sequenceof T. maritima acetyl xylan esterase (SEQ ID NO:41) in the plasmidpSW228. The mutations were made using QUIKCHANGE® (Stratagene) accordingto the manufacturer's instructions. Amplified plasmids were treated with1U of Dpnl at 37° C. for 1 hour. Treated plasmids were used to transformchemically competent E. coli XL1-Blue (Stratagene). Transformants wereplated on LB-agar supplemented with 0.1 mg ampicillin/mL and grownovernight at 37° C. Up to five individual colonies were picked and theplasmid DNA sequenced to confirm the expected mutations.

TABLE 6 Oligonucleotides used to change residue 277 in T. maritima.forward 5′ to 3′ reverse 5′ to 3′ Tma_C277Vf ggacaacatcGTGcctccttctaTma_C277Vr TAGAAGGAGGCACGATGTTGTCC (SEQ ID NO: 194) (SEQ ID NO: 195)Tma_C277Af ggacaacatcGCGcctccttcta Tma_C277Ar TAGAAGGAGGCGCGATGTTGTCC(SEQ ID NO: 196) (SEQ ID NO: 197) Tma_C277Sf ggacaacatcTCAcctccttctaTma_C277Sr TAGAAGGAGGTGAGATGTTGTCC (SEQ ID NO: 198) (SEQ ID NO: 199)Tma_C277Tf ggacaacatcACCcctccttcta Tma_C277Tr TAGAAGGAGGGGTGATGTTGTCC(SEQ ID NO: 200) (SEQ ID NO: 201)

Example 12 Expression of Thermotoga maritima Acetyl Xylan EsteraseVariants in E. coli KLP18

Plasmids with confirmed acetyl xylan esterase mutations were used totransform E. coli KLP18 (Example 1). Transformants were grown in LBmedia at 37° C. with shaking up to 01D_(600nm)=0.4-0.5, at which timeIPTG was added to a final concentration of 1 mM, and incubationcontinued for 2-3 h. Cells were harvested by centrifugation and SDS-PAGEwas performed to confirm expression of the acetyl xylan esterase at20-40% of total soluble protein.

Example 13 Preparation of Cell Lysates Containing Semi-Purified T.Maritima Acetyl Xylan Esterase Mutants

Cell cultures (prepared as described in Example 12) were grown using afermentation protocol similar to that described in Example 7 at a 1-Lscale (Applikon). Cells were harvested by centrifugation at 5,000×g for15 minutes then resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0supplemented with 1.0 mM DTT. Resuspended cells were passed through aFrench pressure cell twice to ensure >95% cell lysis. Lysed cells werecentrifuged for 30 minutes at 12,000×g, and the supernatant was heatedat 75° C. for 20 minutes, followed by quenching in an ice bath for 2minutes. Precipitated protein was removed by centrifugation for 10minutes at 11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the preparation.

Example 14 Specific Activity and Perhydrolysis/Hydrolysis ratio of T.maritima Acetyl Xylan Wild-type Esterase and C277 Esterase Variants

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and one of the following acetyl xylan esterase variants: T. maritimaC277S variant perhydrolase (0.010 mg/mL of heat-treated extract totalprotein from E. coli KLP18/pSW228/C277S), T. maritima C277Tvariantperhydrolase (0.010 mg/mL of heat-treated extract total proteinfrom E. coli KLP18/pSW228/C277T), T. maritima C277A variant perhydrolase(0.0125 mg/mL of heat-treated extract total protein from E. coliKLP18/pSW228/C277A), and T. maritima C277V variant perhydrolase (0.0125mg/mL of heat-treated extract total protein from E. coliKLP18/pSW228/C277V) (prepared as described in Example 13). Reactionswere stirred for only the first 30 seconds of reaction to initially mixthe reactants and enzyme.

A reaction was also run under identical conditions to that describedimmediately above using 0.050 mg/mL of heat-treated extract totalprotein isolated from E. coli KLP18/pSW228 (expressing Thermotogamaritima wild-type acetyl xylan esterase (Example 10)), where theheat-treated extract supernatant was prepared according to the procedureof Example 13.

Two samples from each of the reaction mixtures described above weresimultaneously withdrawn after the first minute of each reaction, andevery two minutes thereafter for fifteen minutes, where one of the twosamples was analyzed for peracetic acid using a modification of themethod described by Karst et al., supra, and the second sample wasanalyzed for total acetic acid produced from both enzymatic hydrolysisof triacetin and from subsequent conversion of peracetic acid in sampleto acetic acid by reaction with methyl-p-tolyl sulfide (MTS) (seeExample 9).

The Thermotoga maritima acetyl xylan esterase mutants had asignificantly-higher specific activity for perhydrolysis of triacetinthan the wild-type esterase (Table 7). The perhydrolysis/hydrolysisratios for the T. maritima acetyl xylan esterase variants weredetermined by dividing the rate of PAA production (perhydrolysis rate)by the rate of hydrolysis of triacetin to acetic acid (hydrolysis rate)(calculated from the rate of total acetic acid production in the assaymethod from both PAA and acetic acid, and corrected for the rate ofperacetic acid production); the P/H ratio of the T. maritima acetylxylan esterase variants were ca. equal to or greater than the P/H ratiofor the T. neapolitana wild-type acetyl xylan esterase (Table 7).

TABLE 7 specific Thermotoga enzyme perhydrolysis hydrolysis activitymaritima concen. rate rate P/H (U/mg perhydrolase (μg/mL) (mM/min)(mM/min) ratio protein) wild type 50 3.06 0.47 6.5 61 C277S 10 7.77 0.4816 777 C277T 10 6.93 1.05 6.6 693 C277A 10 4.27 0.088 48 427 C277V 104.25 0.062 68 425

Example 15 Peracetic Acid Production Using Perhydrolases

Reactions (100 mL total volume) containing triacetin (2 mM), hydrogenperoxide (10 mM) and from 0.1 μg/mL to 2.0 μg/mL heat-treated cellextract protein (prepared as described above, where the heat-treatmentwas performed at 85° C. for 20 min) were run in 10 mM sodium bicarbonatebuffer (initial pH 8.1) at 20° C. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, 20 min, 40 min and 60 min arelisted in Table 8.

TABLE 8 Dependence of peracetic acid (PAA) concentration on perhydrolaseconcentration in reactions containing triacetin (2 mM) and hydrogenperoxide (10 mM) in sodium bicarbonate buffer (10 mM, initial pH 8.1) at20° C., using heat-treated extract protein from E. coli KLP18/pSW228(Thermotoga maritima wild-type perhydrolase) or E. coliKLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase)(duplicate reactions). Thermotoga enzyme PAA, PAA, PAA, PAA, PAA,maritima concen. 1 min 5 min 20 min 40 min 60 min perhydrolase triacetin(mM) (μg/mL) (ppm) (ppm) (ppm) (ppm) (ppm) no enzyme 2 0 0 0 1 1 3 wildtype 2 0.2 0 2 7 13 19 wild type 2 0.2 0 1 5 11 15 wild type 2 0.5 0 212 19 25 wild type 2 0.5 0 2 12 21 26 wild type 2 1.0 0 5 20 29 31 wildtype 2 1.0 0 5 19 30 31 wild type 2 2.0 1 11 24 24 20 wild type 2 2.0 111 29 29 21 C277S 2 0.2 0 4 18 18 18 C277S 2 0.2 0 4 18 17 18 C277S 20.5 1 12 39 54 64 C277S 2 0.5 1 10 34 52 64 C277S 2 1.0 18 26 59 69 63C277S 2 1.0 18 25 60 70 64 C277S 2 2.0 9 38 66 60 48 C277S 2 2.0 9 34 6961 49

Example 16 Peracetic Acid Production Using Perhydrolases

Reactions (100 mL total volume) containing triacetin (20 mM), hydrogenperoxide (10 mM) and from 0.1 μg/mL to 2.0 μg/mL heat-treated cellextract protein (prepared as described above, where the heat-treatmentwas performed at 85° C. for 20 min) were run in 10 mM sodium bicarbonatebuffer (initial pH 8.1) at 20° C. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, 20 min, 40 min and 60 min arelisted in Table 9.

TABLE 9 Dependence of peracetic acid (PAA) concentration on perhydrolaseconcentration in reactions containing triacetin (20 mM) and hydrogenperoxide (10 mM) in sodium bicarbonate buffer (10 mM, initial pH 8.1) at20° C., using heat-treated extract protein from E. coli KLP18/pSW228(Thermotoga maritima wild-type perhydrolase) or E. coliKLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase)(duplicate reactions). Thermotoga enzyme PAA, PAA, PAA, PAA, PAA,maritima concen. 1 min 5 min 20 min 40 min 60 min perhydrolase triacetin(mM) (μg/mL) (ppm) (ppm) (ppm) (ppm) (ppm) no enzyme 20 0 2 3 3 7 9wild-type 20 0.2 3 10 15 27 35 wild-type 20 0.2 4 9 19 32 41 wild-type20 0.5 3 9 21 39 52 wild-type 20 0.5 3 8 22 39 54 wild-type 20 1.0 4 1335 62 82 wild-type 20 1.0 4 12 37 67 wild-type 20 2.0 9 20 52 91 122wild-type 20 2.0 10 20 52 87 114 C277S 20 0.2 7 16 67 109 148 C277S 200.2 9 24 67 112 144 C277S 20 0.5 16 43 140 202 260 C277S 20 0.5 17 48148 228 272 C277S 20 1.0 24 75 230 289 353 C277S 20 1.0 26 97 232 297372 C277S 20 2.0 32 130 318 402 443 C277S 20 2.0 37 135 323 401 430

Example 17 Peracetic Acid Production Using Perhydrolases

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and from 10 μg/mL to 50 μg/mL of heat-treated T. neapolitana or T.maritima wild-type or C277 variant perhydrolases (as heat-treated cellextract protein prepared as described above, where the heat-treatmentwas performed at 75° C. for 20 min). Reactions were stirred for only thefirst 30 seconds of reaction to initially mix the reactants and enzyme.Determination of the concentration of peracetic acid in the reactionmixtures was performed according to the method described by Karst etal., supra. The peracetic acid concentrations produced in 1 min, 5 min,and 30 min are listed in Table 10.

TABLE 10 Peracetic acid (PAA) production in reactions containingtriacetin (100 mM) and hydrogen peroxide (100 mM) in phosphate buffer(50 mM, pH 7.2) at 25° C., using heat-treated T. neapolitana or T.maritima wild-type or C277 mutant perhydrolases. enzyme PAA, PAA, PAA,H₂O₂ concen. 1 min 5 min 30 min perhydrolase triacetin (mM) (mM) (μg/mL)(ppm) (ppm) (ppm) no enzyme 100 100 0 63 54 80 T. maritima wild-type 100100 50 529 1790 3785 T. maritima C277S 100 100 10 979 3241 4635 T.maritima C277T 100 100 10 933 2882 3527 T. maritima C277A 100 100 10 4422018 2485 T. maritima C277V 100 100 10 577 1931 2278 T. neapolitanawild-type 100 100 50 514 1837 3850 T. neapolitana C277S 100 100 10 6062237 4609 T. neapolitana C277T 100 100 10 634 2198 3918 T. neapolitanaC277A 100 100 12.5 516 2041 3735 T. neapolitana C277V 100 100 12.5 4511813 2758

Example 18 Peracetic Acid Production Using Perhydrolases

Reactions (10 mL total volume) were run at 25° C. in sodium bicarbonatebuffer (1 mM, initial pH 6.0) containing triacetin (100 mM or 150 mM),hydrogen peroxide (100 mM, 250 mM or 420 mM) and heat-treated T.neapolitana or T. maritima wild-type, C277S or C277T vacantperhydrolases (as heat-treated cell extract protein prepared asdescribed above, where the heat-treatment was performed at 75° C. for 20min; concentrations as listed in Table 11). Reactions run using 420 mMhydrogen peroxide additionally contained 500 ppm TURINAL® SL. Reactionswere stirred for only the first 30 seconds of reaction to initially mixthe reactants and enzyme. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, and 30 min are listed in Table11.

TABLE 11 Peracetic acid (PAA) production in reactions containingtriacetin and hydrogen peroxide in bicarbonate buffer (1 mM at pH 6.0 or100 mM at pH 8.1) or in deionized water (pH 5.0) at 25° C. usingheat-treated T. maritima wild- type, C277S or C277T variantperhydrolases. Thermotoga NaHCO₃ enzyme PAA, PAA, PAA, maritima H₂O₂buffer concen. 1 min 5 min 30 min perhydrolase triacetin (mM) (mM) (mM)(μg/mL) (ppm) (ppm) (ppm) no enzyme 100 100 1.0 0 28 78 141 wild-type100 100 1.0 75 434 494 608 wild-type 100 100 1.0 100 449 667 643 C277S100 100 1.0 15 989 1554 1476 C277S 100 100 1.0 20 1301 2139 2131 C277T100 100 1.0 15 1062 1513 1393 C277T 100 100 1.0 20 996 1430 1516 noenzyme 100 250 0 0 13 71 71 wild-type 100 250 0 75 512 535 533 wild-type100 250 0 100 576 668 654 C277S 100 250 0 15 653 671 675 C277S 100 250 020 943 927 903 C277T 100 250 0 15 717 711 765 C277T 100 250 0 20 730 755743 no enzyme 150 420 100 0 417 810 848 wild-type 150 420 100 500 63038627 9237 C277S 150 420 100 100 7822 10349 10197

Example 19 Perhydrolysis of Propylene Glycol Diacetate or EthyleneGlycol Diacetate Using T. maritima and T. neapolitana Wild-Type andVariant Perhydrolases

Cell extracts of transformants expressing Thermotoga neapolitanawild-type perhydrolase (KLP18/pSW196), Thermotoga neapolitana C277Svariant perhydrolase (KLP18/pSW196/C2775), Thermotoga neapolitana C277Tvariant perhydrolase (KLP18/pSW196/C277T), Thermotoga maritima wild-typeperhydrolase (KLP18/pSW228), Thermotoga maritima C277S variantperhydrolase (KLP18/pSW228/C277S), and Thermotoga maritima C277T variantperhydrolase (KLP18/pSW228/C277T) were each prepared by passing asuspension of cell paste (20 wt % wet cell weight) in 0.05 M potassiumphosphate buffer (pH 7.0) containing dithiothreitol (1 mM) twice througha French press having a working pressure of 16,000 psi (˜110 MPa). Thelysed cells were centrifuged for 30 minutes at 12,000×g, producing aclarified cell extract that was assayed for total soluble protein(Bradford assay). The supernatant was heated at 75° C. for 20 minutes,followed by quenching in an ice bath for 2 minutes. Precipitated proteinwas removed by centrifugation for 10 minutes at 11,000×g. SDS-PAGE ofthe resulting heat-treated extract protein supernatant indicated thatthe CE-7 enzyme comprised approximately 85-90% of the total protein inthe preparation. The heat-treated extract protein supernatant was frozenin dry ice and stored at −80° C. until use.

A first set of reactions (10 mL total volume) were run at 20° C. in 10mM sodium bicarbonate buffer (initial pH 8.1) containing propyleneglycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) (100 mM),hydrogen peroxide (100 mM) and 25 μg/mL of heat-treated extract proteinfrom one of E. coli KLP18/pSW196 (Thermotoga neapolitana wild-typeperhydrolase), E. coli KLP18/pSW196/C277S (Thermotoga neapolitana C277Svariant perhydrolase), E. coli KLP18/pSW196/C277T (Thermotoganeapolitana C277T variant perhydrolase), E. coli KLP18/pSW228(Thermotoga maritime wild-type perhydrolase), E. coli KLP18/pSW228/C277S(Thermotoga maritime C277S variant perhydrolase), and E. coliKLP18/pSW228/C277T (Thermotoga maritime C277T variant perhydrolase)(prepared as described above). A control reaction for each reactioncondition was run to determine the concentration of peracetic acidproduced by chemical perhydrolysis of triacetin by hydrogen peroxide inthe absence of added extract protein. The reactions were sampled at 1,5, and 30 minutes and the samples analyzed for peracetic acid using theKarst derivatization protocol (Karst et al., supra) and HPLC analyticalmethod (supra). The peracetic acid concentrations produced in 1 min, 5min and 30 min are listed in Table 12.

TABLE 12 Peracetic acid (PAA) concentration produced utilizing T.maritima and T. neapolitana wild-type and variant perhydrolases inreactions at 20° C. in sodium bicarbonate buffer (10 mM, initial pH 8.1)containing propylene glycol diacetate (PGDA) (100 mM) or ethylene glycoldiacetate (EGDA) (100 mM), hydrogen peroxide (100 mM) and 25 μg/mL ofheat-treated extract protein. substrate PAA, PAA, PAA, sub- conc. H₂O₂ 1min 5 min 30 min perhydrolase strate (mM) (mM) (ppm) (ppm) (ppm) noenzyme PGDA 100 100 0 15 165 (control) T. maritima PGDA 100 100 534 11041695 WT T. maritima PGDA 100 100 647 1320 1864 C277S T. maritima PGDA100 100 656 1174 1418 C277T T. neapolitana PGDA 100 100 513 1052 1946 WTT. neapolitana PGDA 100 100 875 1327 1707 C277S T. neapolitana PGDA 100100 724 1325 1864 C277T no enzyme EGDA 100 100 0 70 229 (control) T.maritima EGDA 100 100 765 1182 1595 WT T. maritima EGDA 100 100 725 12401724 C277S T. maritima EGDA 100 100 802 1218 1734 C277T T. neapolitanaEGDA 100 100 603 1132 1643 WT T. neapolitana EGDA 100 100 680 1305 1698C277S T. neapolitana EGDA 100 100 688 1164 1261 C277T

A second set of reactions (10 mL total volume) were run at 20° C. in 10mM sodium bicarbonate buffer (initial pH 8A) containing propylene glycoldiacetate (PGDA) or ethylene glycol diacetate (EGDA) (2 mM), hydrogenperoxide (10 mM) and 10 μg/mL of heat-treated extract protein from oneof E. coli KLP18/pSW196 (Thermotoga neapolitana wild-type perhydrolase),E. coli KLP18/pSW196/C2778 (Thermotoga neapolitana C277S variantperhydrolase), E. coli KLP18/pSW196/C277T (Thermotoga neapolitana C277Tvariant perhydrolase), E. coli KLP18/pSW228 (Thermotoga maritimawild-type perhydrolase), E. coli KLP18/pSW228/C277S (Thermotoga maritimaC277S variant perhydrolase), and E. coli KLP18/pSW228/C277T (Thermotogamaritima C277T variant perhydrolase) (prepared as described above). Acontrol reaction for each reaction condition was run to determine theconcentration of peracetic acid produced by chemical perhydrolysis oftriacetin by hydrogen peroxide in the absence of added extract protein.The reactions were sampled at 5 minutes and the samples analyzed forperacetic acid using the Karst derivatization protocol (Karst et al.,supra) and HPLC analytical method (supra). The peracetic acidconcentrations produced in 5 min are listed in Table 13.

TABLE 13 Peracetic acid (PAA) concentration produced utilizing T.maritima and T. neapolitana wild-type and variant perhydrolases inreactions at 20° C. in sodium bicarbonate buffer (10 mM, initial pH 8.1)containing propylene glycol diacetate (PGDA) (2 mM) or ethylene glycoldiacetate (EGDA) (2 mM), hydrogen peroxide (10 mM) and 10 μg/mL ofheat-treated extract protein. substrate PAA, conc. H₂O₂ 5 minperhydrolase substrate (mM) (mM) (ppm) no enzyme (control) PGDA 2 10 3.6T. maritima WT PGDA 2 10 5.0 T. maritima C277S PGDA 2 10 7.2 T. maritimaC277T PGDA 2 10 7.9 T. neapolitana WT PGDA 2 10 5.7 T. neapolitana C277SPGDA 2 10 7.9 T. neapolitana C277T PGDA 2 10 3.9 no enzyme (control)EGDA 2 10 3.3 T. maritima WT EGDA 2 10 9.9 T. maritima C277S EGDA 2 1013.6 T. maritima C277T EGDA 2 10 22.9 T. neapolitana WT EGDA 2 10 6.6 T.neapolitana C277S EGDA 2 10 18.4 T. neapolitana C277T EGDA 2 10 20.2

1. An isolated polynucleotide encoding a polypeptide havingperhydrolysis activity, said polypeptide being structurally classifiedas a carbohydrate esterase family 7 enzyme and (a) having at least 95%amino acid sequence identity to SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO:15, SEQ ID NO: 20, or SEQ ID NO: 25, provided that a substitution toamino acid residue 277 of SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 15,SEQ ID NO: 20, or SEQ ID NO: 25 is selected from the group consisting ofserine, threonine, valine, and alanine or (b) having at least 95% aminoacid sequence identity to SEQ ID NO: 30, provided that a substitution toamino acid residue 278 of SEQ ID NO: 30 is selected from the groupconsisting of serine, threonine, valine, and alanine.
 2. The isolatedpolynucleotide of claim 1, wherein the polypeptide comprises SEQ ID NO:5, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25 or SEQ IDNO:
 30. 3. The isolated polynucleotide of claim 1, wherein thepolynucleotide comprises a nucleic acid sequence selected from the groupconsisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11,SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO:17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ IDNO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, andSEQ ID NO:
 29. 4. A vector comprising the polynucleotide of claim
 1. 5.A recombinant DNA construct comprising the polynucleotide of claim 1operably linked to a regulatory sequence.
 6. A host cell comprising therecombinant DNA construct of claim
 5. 7. A method for transforming acell, comprising transforming a cell with the polynucleotide of claim 1.8. An isolated polypeptide having perhydrolysis activity and beingstructurally classified as a carbohydrate esterase family 7 enzyme, saidpolypeptide having at least 95% amino acid sequence identity to (a) SEQID NO: 5, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 20, or SEQ ID NO: 25,provided that a substitution to amino acid 277 of SEQ ID NO: 5, SEQ IDNO: 10, SEQ ID NO: 15, SEQ ID NO: 20, or SEQ ID NO: 25 is selected fromthe group consisting of serine, threonine, valine, and alanine; or (b)SEQ ID NO: 30, provided that a substitution to amino acid 278 of SEQ IDNO: 30 is selected from the group consisting of serine, threonine,valine, and alanine.
 9. The isolated polypeptide of claim 8, wherein thepolypeptide comprises amino acid sequence SEQ ID NO: 5, SEQ ID NO: 10,SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, or SEQ ID NO:
 30. 10. Aprocess for producing a peroxycarboxylic acid from a carboxylic acidester comprising (a) providing a set of reaction components, saidcomponents comprising: (1) a carboxylic acid ester selected from thegroup consisting of: (i) one or more esters having the structure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (ii) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (iii) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; (iv) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (v) any combination of (i) through (iv); (2) asource of peroxygen; and (3) the polypeptide of claim 8; and (b)combining said reaction components under suitable aqueous reactionconditions whereby a peroxycarboxylic acid is produced.
 11. A process todisinfect or sanitize a hard surface or inanimate object using anenzymatically-produced peroxycarboxylic acid composition, said processcomprising: (a) providing a set of reaction components, said componentscomprising: (1) a carboxylic acid ester selected from the groupconsisting of: (i) one or more esters having the structure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (ii) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (iii) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; (iv) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (v) any combination of (i) through (iv); (2) asource of peroxygen; and (3) the polypeptide of claim 8; (b) combiningsaid reaction components under suitable aqueous reaction conditionswhereby a peroxycarboxylic acid product is formed; (c) optionallydiluting said peroxycarboxylic acid product; and (d) contacting saidhard surface or inanimate object with the peroxycarboxylic acid producedin step (b) or step (c) whereby said surface or said inanimate object isdisinfected or sanitized.
 12. A process for treating an article ofclothing or a textile for bleaching, stain removal, odor reduction,sanitization or disinfection using an enzymatically-producedperoxycarboxylic acid composition, said process comprising: (a)providing a set of reaction components, said components comprising: (1)a carboxylic acid ester selected from the group consisting of: (i) oneor more esters having the structure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (ii) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (iii) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; (iv) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (v) any combination of (i) through (iv); (2) asource of peroxygen; and (3) the polypeptide of claim 8; (b) combiningsaid reaction components under suitable aqueous reaction conditionswhereby a peroxycarboxylic acid product is formed; (c) optionallydiluting said peroxycarboxylic acid product; and (d) contacting saidarticle of clothing or textile with the peroxycarboxylic acid producedin step (b) or step (c); wherein said article of clothing or textile isdestained, deodorized, disinfected, bleached, or a combination thereof.13. A peroxycarboxylic acid generating system comprising: (a) asubstrate selected from the group consisting of: (i) one or more estershaving the structure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (ii) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (iii) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; (iv) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (v) any combination of (i) through (iv); (b) asource of peroxygen; and (c) the polypeptide of claim
 8. 14. Aformulation comprising: (a) a first mixture comprising an enzymecatalyst comprising the polypeptide of claim 8 and a carboxylic acidester selected from the group consisting of monoacetin, diacetin,triacetin and mixtures thereof; said first mixture optionally comprisingan inorganic or organic buffer, a corrosion inhibitor, a wetting agentor a combination thereof; and (b) a second mixture comprising a sourceof peroxygen and water, said second mixture optionally furthercomprising a hydrogen peroxide stabilizer.
 15. A formulation comprising:(a) a first mixture comprising a enzyme catalyst comprising thepolypeptide of claim 8 and an acetylated saccharide selected from thegroup consisting of acetylated monosaccharides, acetylateddisaccharides, acetylated polysaccharides, and combinations thereof,said first mixture optionally further comprising an inorganic or organicbuffer, a corrosion inhibitor, a wetting agent, or a combinationthereof; and (b) a second mixture comprising a source of peroxygen andwater, said second mixture optionally comprising a hydrogen peroxidestabilizer.
 16. An isolated polynucleotide encoding a Thermotoga acetylxylan esterase polypeptide having perhydrolysis activity, wherein thepolypeptide comprises the C-terminal conserved region of SEQ ID NO:31,provided that the polypeptide has a substitution to amino acid 93 of SEQID NO:31 selected from the group consisting of serine, threonine,valine, and alanine.
 17. An isolated Thermotoga acetyl xylan esterasepolypeptide, wherein said polypeptide has perhydrolysis activity andcomprises the C-terminal conserved region of SEQ ID NO:31, provided thatthe polypeptide has a substitution to amino acid 93 of SEQ ID NO:31selected from the group consisting of serine, threonine, valine, andalanine.
 18. A process to provide a benefit to an article of clothing ortextile using an enzymatically-produced peroxycarboxylic acidcomposition, said process comprising: (a) providing a set of reactioncomponents, said components comprising: (1) a carboxylic acid esterselected from the group consisting of: (i) one or more esters having thestructure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (ii) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (iii) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n),H and n is 1 to 10; (iv) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (v) any combination of (i) through (iv); (2) asource of peroxygen; and (3) the polypeptide of claim 8; (b) combiningsaid reaction components under suitable aqueous reaction conditionswhereby a peroxycarboxylic acid product is formed; (c) optionallydiluting said peroxycarboxylic acid product; and (d) contacting saidarticle of clothing or textile with the peroxycarboxylic acid producedin step (b) or step (c) whereby said article of clothing or textilereceives a benefit selected from the group consisting of bleaching,destaining, deodorizing, disinfecting, sanitizing, and a combinationthereof.